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Abstract 
 
Pelvic Inflammatory Disease (PID) is one of the most common causes of morbidity in 
women. PID is a polymicrobial infection of the female reproductive tract, and is 
associated with pelvic pain, abnormal uterine bleeding, and tubal damage that can lead 
to ectopic pregnancies and infertility. It is curable but the effects of PID can be 
permanent if not properly diagnosed and treated. PID presents as a spectrum of disease 
and is often missed at early stages; even acute PID can be difficult to diagnose, as there 
is no single conclusive diagnostic test. Currently, PID is identified and treated 
syndromically because pelvic pain is the only consistent clinical finding. The Center for 
Disease Control and Prevention (CDC) recommends doxycycline, a broad-spectrum 
antibiotic, for treatment but doxycycline can cause gastrointestinal irritation and local 
inflammation leading to an incomplete treatment. Most cases of PID are polymicrobial 
infections of the tubes and endometrium, which are not accessible to culture due to the 
difficulty of procuring samples above the naturally contaminated vagina and distal cervix. 
Given the difficulty of properly diagnosing PID and the limitations and side effects of the 
current treatments, there is an urgent need for new approaches for improving the 
accuracy for diagnosis and treatment of PID. We propose a new and practical approach 
to collect sterile specimen samples from the endometrium for more accurate PID 
diagnosis, and to treat the reproductive tract locally using doxycycline-loaded 
nanoparticles. The proposed research presents a novel sterile uterine sampler cover 
(SUSC) device that can safely and effectively collect uncontaminated specimen samples 
from the uterus, and also deliver nano-encapsulated drugs directly to the site of 
 viii 
infection. The analysis of uncontaminated endometrium samples is expected to provide 
an understanding of uterine flora in symptomatic and asymptomatic women, and will 
lead to the identification of infective microbes in symptomatic women for pathogen-
specific treatment. The use of nano-encapsulated doxycycline will enable localized drug 
delivery to lower drug dosage and minimize side effects for the patient. The doxycycline-
loaded nanoparticles are characterized and evaluated based on their drug release 
properties, size distribution, and tissue response in vitro. This research will lead towards 
a more effective approach for the diagnosis and treatment of PID while freeing women 
from prolonged systemic treatments and their adverse effects. Moreover, this research 
will increase our understanding of the uterine biome under various hormonal and 
pathologic conditions, in symptomatic and asymptomatic women. 
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Chapter 1 - Introduction 
1.1. Motivation 
According to the Centers for Disease Control and Prevention (CDC), an estimated 
1.0 million women in the United States experience acute pelvic inflammatory disease 
(PID), and 1–2 billion dollars are spent for PID and its sequelae treatment each year.1-6 
PID is an infection of the upper genital tract, which includes the uterus (endometrium), 
fallopian tubes, and surrounding organs. It is hypothesized that microorganisms such as 
Chlamydia trachomatis, Neisseria gonorrhoeae, and microorganisms of the vagina’s 
normal flora cause PID.7-9 Symptoms associated with PID include pelvic pain, abnormal 
uterine bleeding, and vaginal discharge. The reproductive infection can also result in 
tubal damage, which can lead to ectopic pregnancies and infertility.2,4,8,10,11 
Unrecognized (dormant) infection is thought to be associated with preterm labor, and 
neonatal mortality. Approximately 33% of severe PID cases are reportedly incorrectly 
diagnosed, --a lack of reliable and conclusive diagnostic testing can make detection of 
acute PID very difficult.3,12,13 And in its early stages, PID often goes undiagnosed as 
symptoms can be subtle.14 
Current PID diagnosis is based on CDC recommended minimal diagnostic criteria: 
pelvic pain as cervical motion tenderness, uterine tenderness and/or adnexal 
tenderness.15 Evidence of lower genital tract inflammation—leukocytes in vaginal 
secretions, cervical exudates or bleeding on contact--increases the likelihood of PID as a 
cause for pelvic pain. Other supportive but not necessary findings include: temperature 
above 38.3°C, an elevated erythrocyte sedimentation rate, elevated serum levels of C-
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reactive protein, prior or current N. gonorrhoeae or C. trachomatis infections, or an 
inflamed mass on pelvic sonography.10,13 Along with the CDC criteria, medical history 
especially risk factors, physical examination, and a few laboratory tests, including C 
reactive protein, peripheral white cell count, and erythrocyte sedimentation rate, and 
cervical testing for C trachomatis and N gonorrhea constitute the usual methods for 
diagnosing PID. The sensitivity and specificity of these laboratory test approaches 
ranges from for poor to fair when it comes to diagnosing PID.8,10 It has long been 
observed that women with no history of recognized PID often present with tubal factor 
infertility.16-18 Persistent Chlamydia in the upper reproductive tract was identified in 15% 
of 52 women undergoing tubal surgery for infertility.19 Chlamydia was found in the 
peritoneal fluid in 44% of women laparoscoped for pelvic pain with signs of salpingitis, 
and in 37% of women undergoing surgery for tubal sterility.20 Recent data have 
broadened recognition of subclinical PID (15) as identified by the presence of leukocytes 
and plasma cells in an endometrial biopsy.14 However, use of endometrial tissue for 
microbial identification has not been adequately tested using modern genetic 
identification techniques. Neither have the normal flora of the healthy uterine cavity been 
characterized. 
Ultrasound is useful for detecting overt inflammatory changes in pelvic organs, but 
has poor sensitivity when these are minimal.1,10,21 The current gold standard for 
diagnosing PID is laparoscopy, a minimally invasive surgery, to provide physical 
evidence and allow upper tract sampling. However, this is a resource intensive 
procedure requiring general anesthesia with significant risk.10,22,23 Empirical antibiotic 
therapy that covers both Chlamydia trachomatis and Neisseria gonorrhorrhea is the first 
line of treatment. The patient is then monitored to determine if or when symptoms 
subside, while awaiting test results for cervical evidence of Chlamydia or gonorrhea.1 
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The CDC recommends doxycycline, an inexpensive, widely available broad-
spectrum antibiotic, which obtains very high drug levels in the pelvic area, as a key 
component of treatment. However, this drug can cause gastrointestinal irritation when 
taken orally, and requires a two-week treatment course. Doxycycline may also cause 
local inflammation when given intravenously. These side effects often result in 
incomplete treatment. Current gynecological devices for collecting endometrium cannot 
provide sterile samples, hence the reliance on evidence of inflammation in endometrial 
biopsies as sole evidence of ‘subclinical’ upper tract infection in women with minimal 
pain. Analysis of uncontaminated endometrial tissue is expected to provide an accurate 
diagnosis of local inflammation and identify the specific organisms causing it, guiding the 
selection of the best treatment. As is currently done with urinary tract infections, drugs 
can be started using current assumptions, and corrected as needed after data is 
available. Equally importantly, uncontaminated endometrial sampling will allow a better 
understanding of the natural microbial ecology of the uterus under a variety of 
spontaneous and manipulated hormonal conditions. It is highly likely that biofilms of 
sessile pathogens exist in the endometrial cavity as they do in the inner ear, bladder, 
and prostate, and this has enormous implications for fertility and complications of 
pregnancy. 
The lack of accurate diagnostic methods and/or devices has severely limited 
understanding of PID, particularly those episodes of inflammation which are associated 
with bowel commensals rather than Chlamydia and gonorrhea, or produce recurrent 
symptoms, or occur in apparently low risk women. We hope to avoid delayed treatment 
in atypical cases, and overtreatment when there is no infection. Once pathogens are 
identified, we believe that local treatment may be more effective than systemic, as is 
done in dairy cows.24 Development of a new topical treatment approach requires 
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reformulation of currently used drugs for minimal toxicity and effective application—
ideally transvaginally by the patient herself. 
 
1.2. Dissertation Objectives and Contributions 
Given the difficulty of properly diagnosing PID and the limitations and side effects of 
the current treatments, there is an urgent need for new approaches to improve the 
diagnostic accuracy and treatment of PID. We set out to: (a) design and validate a new 
device to collect uncontaminated samples from the endometrium for more accurate 
diagnosis of PID, and (b) design and analyze the encapsulation of doxycycline into 
nanoparticles for targeted drug delivery. The objectives of this research are: 
1. To design and validate a sterile uterine sampler device capable of 
collecting sterile samples from the endometrium 
2. To analyze the preparatory variables associated with chitosan 
nanoparticle preparation via the ionic gelation method 
3. To evaluate the doxycycline-loaded chitosan nanoparticles in vitro for 
antibacterial activity on E. coli cultures and cytotoxicity on normal human 
ovarian surface epithelial cells 
This approach is intended to provide a simple and accurate method of obtaining 
specimens of uterine, cervical and vaginal flora separately. DNA analysis of the 
specimens should demonstrate the uterine biome in both symptomatic and 
asymptomatic women, stratified by treatment and hormonal status. Conventional culture 
or quantitative analysis of the microbial populations that are identified as well as immune 
histology may demonstrate infectious agents, as distinct from commensals. New 
strategies may be then devised for diagnosis, treatment and prevention of reproductive 
tract infection. Nanoformulation of doxycycline may provide better, targeted therapy with 
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less toxicity than systemic treatment to reduce the prescribed dosage and side effects 
associated with the disease's common drug treatments. 
The findings described in this body of work have the potential to decrease adverse 
health consequences and the cost of treatment, thus improving the quality of life of 
patients suffering from PID. This work can also help to define and compare the vaginal 
and uterine flora—both infectious (culturable) and vegetative (biofilms)—in 
asymptomatic and symptomatic women under various hormonal conditions, and it may 
allow immediate local delivery of an appropriate nano-encapsulated drug. 
Uncontaminated tissue samples will allow a better understanding of the natural microbial 
ecology of the uterus, and this improved understanding will impact both gynecological 
and obstetrical practice. 
 
1.3. Dissertation Outline 
This dissertation is organized as follows. Chapter 2 presents an in-depth literature 
review. Chapter 3 presents the design and development of the proposed sterile uterine 
sampler device. Chapter 4 focuses on the analysis of the preparation of doxycycline-
loaded nanoparticles. Chapter 5 describes the in vitro analysis of these nanoparticles 
based on their function (antibacterial activity) and biological safety (cytotoxicity). Finally, 
Chapter 6 summarizes the relevant findings of the dissertation and presents 
recommendations for future directions.   
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Chapter 2 - Literature Review 
 
This chapter provides some background on current uterine sampling devices. An 
overview of previous work on targeted drug delivery techniques, nanoparticle 
preparation, and the drug doxycycline are also presented. 
 
2.1. Uterus Sampling Devices 
Devices that can be inserted into the uterus have been developed for endometrial 
sampling, pregnancy prevention, and other gynecological procedures. Examples include 
the select cell, transcervical devices, intrauterine devices (IUDs), and curettes. IUDs are 
small devices implanted into the uterus for a certain period of time to prevent pregnancy 
by disrupting the uterine wall or slowly releasing hormones.25-27 The curette is a metal 
rod with a handle at one end and a loop on the other end that is used to scrape the lining 
of the uterus during a gynecological procedure called "dilation and curettage.28 This 
procedure was considered the gold standard for sampling the endometrium for more 
than a century.29,30 
In 1949, Guilbeau et al. proposed a uterine culture technique for sampling the 
endometrium of postpartum women while avoiding the contaminated cervical and 
vaginal areas.31-33 They suggested using a metal tube with a tightly drawn finger cot 
(which required chemical sterilization for 48 hours) to occlude the distal end of the cervix 
and prevent contamination during insertion. Once inserted with a stylet beyond the 
internal os of the cervix, the finger cot was pierced, thus allowing the inner wire loop to 
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collect the sample. However, this technique was merely described; no data were 
presented to document its efficacy. 
In 1981, Knuppel et al. presented a transcervical device for sampling the uterus.32 
This specimen collection device consisted of a telescoping Teflon catheter that housed a 
nylon bristle brush attached to a retractable wire in the inner cannula. At the tip of the 
outer catheter was a plug made of either gelfoam or polyethylene glycol. Upon insertion 
of the device, the brush was used to push the plug into the uterus to allow the brush to 
collect the specimen. Leaving the plug in the uterus was a major drawback. A plug made 
of polyethylene glycol would take a couple of days to dissolve; a plug made of gelfoam 
could cause a nidus of infection. This device was designed to pass through the 
contaminated vaginal and cervical area to the uterus for specimen collection. This device 
does not protect the uterine sample from the contaminated vagina and cervix, and it 
leaves the plug portion of the device inside the uterus. 
Another technique for culturing the uterus was described by Bollinger.33,34 In this 
technique, a Teflon sheath with a Teflon plug was used to reach the uterus. Once inside 
the uterus, the plug was dislodged by an inner cannula to which a syringe was attached 
for suction of the specimen sample. The accuracy of this approach was not clearly 
defined due to the fact that the device used for sampling passes through the 
contaminated areas of the cervix and vagina. 
Between 1981 and 1982, Patrick Duff and his team investigated four different 
endometrial specimen techniques: (1) transfundal aspiration, (2) transcervical brush 
biopsy through a double-lumen catheter, (3) transcervical lavage through a double-
lumen catheter, and (4) aspiration of secretions from the lower uterine segment through 
a single-lumen catheter.33 For the transfundal aspiration, an 18-gauge spinal needle 
preloaded with sterile polyionic solution is used. Once in the endometrium cavity, the 
solution was injected through the needle and then immediately aspirated back into the 
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needle. Knuppel et al described the transcervical double-lumen catheter technique.32,33 
For the transcervical lavage, a sterile polyionic solution was injected in the endometrium 
cavity through an inner catheter passing through an outer catheter. This injection was 
followed by immediate re-aspiration. For the fourth technique, aspiration of lower-uterine 
secretions, a catheter was placed 4 cm above the external os of the cervix and a 
polyionic solution was then injected and immediately re-aspirated. These techniques 
were all conducted on uninfected women in the Trendelenburg position. It was observed 
that the brush biopsy and lavage through double-lumen catheter were the most 
satisfactory techniques for reducing but not preventing cervical and vaginal 
contamination. 
The select cell©, a newer and smaller version of the Pipelle, is another device used 
to collect endometrial specimens.29 The select cell, which removes specimens through 
suction, is made of a clear, long, and flexible polypropylene sheath with an acetal 
copolymer rod to which a piston is molded. As with the transcervical devices, the 
specimen collected by the select cell is not protected from the contaminated vaginal and 
cervical areas during sampling. 
Other endometrium samplers and/or techniques have been patented as shown in 
Table 2-1. However, none of the currently available or patented devices and/or 
techniques can procure truly uncontaminated specimen samples from the endometrium 
and surrounding areas. Sterile samples are necessary for a better understanding of not 
only normal flora in asymptomatic women but also improved understanding and 
diagnosis of upper genital tract infection in symptomatic women. One of the objectives of 
this dissertation research is to design and develop a novel sterile uterine sampler cover 
(SUSC) device to collect sterile specimen samples from the fallopian tubes, uterus, and 
surrounding areas to improve the accuracy of diagnosis of pelvic inflammatory disease 
(PID). Once the disease-causing organism(s) are identified, the proper drug treatment 
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can be recognized. To improve the treatment drug’s efficacy, the drug can be 
encapsulated into nanoparticles for targeted drug delivery. This device can potentially be 
used to deliver drug-loaded particles via a transcervical route for more localized drug 
treatment of PID. 
 
Table 2-1: List of some patented uterus sampling devices. 
Year Author(s) Patent Title  Reference 
1973 Binard 
Dye 
Endometrial Sampler 35 
1982 Shah Medical Device for Collecting Body 
Sample  
36 
1983 Milgrom Tissue Collecting Apparatus  37 
1984 Kotsifas 
Wetzel 
Gilson 
Endometrial Sampling Device 38 
1990 Neuwirth 
Bolduc 
Intrauterine Cauterizing Apparatus 39 
2003 Anapliotis Device for Taking Biological or 
Cytological Smear 
40 
2008 Gruber Systems, Methods, and Devices for 
Performing Gynecological 
Procedures 
41 
2008 Alderete 
Castella 
Method and Device for 
Trichomonas Detection 
42 
2009 Lee-Sepsick 
Azevedo 
Currie 
Methods and Devices for Conduit 
Occlusion  
43 
 
2.2. Targeted Drug Delivery 
Targeted drug delivery is a unique method for delivering a drug to one particular site 
of the body in an effort to increase the dosage to that specific location and to reduce 
adverse side effects. There are three main constituents in a targeted drug delivery 
system: a drug, a targeted site, and a delivery vehicle.44 The drug can be either 
chemically conjugated or passively absorbed into the delivery vehicle. The targeted site 
is dictated by the nature and origin of the disease being treated. The delivery vehicle 
(the carrier) is of utmost importance, as it must preserve the pharmacodynamic and 
pharmacokinetic properties of the drug being carried.44 
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To deliver a drug across cell membranes, several vehicle materials can be used—
e.g., natural or synthetic polymers, dendrimers, surfactants, or lipids.45-47 Among the 
natural polymers, chitosan is widely used in drug delivery applications because it is 
biocompatible, biodegradable, and possesses a muco–adhesive property that enables 
its transport across mucosal membranes.48-55 These properties make chitosan highly 
desirable for encapsulating drugs to improve their efficiency, delivery, and controlled 
release, and thereby reduce their toxicity.48-57 
Chitosan is a cationic linear amino-polysaccharide biopolymer derived from the 
deacetylation of chitin (figure 2-1), which is naturally found in the exoskeleton of 
crustaceans.48,52,54,58-61 When chitosan particles are used to deliver a drug, the patient's 
body is capable of breaking down the chitosan into non-toxic amino sugars.62,63 In 
addition, chitosan particles can be manipulated to achieve both passive and active drug 
targeting.44,64  
 
 
 
 
 
 
 
 
Figure 2-1: The chemical structure of chitin and chitosan.  
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2.3. Preparation Methodologies for Chitosan Nanoparticles 
Encapsulation methods are chosen in part based on polymer properties, drug 
hydrophobicity, and desired final particle size. The molecular weight of the chitosan 
plays a vital role in particle size and formation, as a higher molecular weight produces 
larger particles.59,65 Another vital component of preparing drug-loaded nanoparticles is 
the hydrophobicity of the drug.66 Therefore, the selection of the encapsulation method 
depends on the desired particle size, drug hydrophobicity, and polymer surface 
properties to ensure drug encapsulation while minimizing drug loss and maintaining 
pharmacological activity. 
Commonly used methods for preparing chitosan-based drug delivery systems 
include emulsion cross-linking,63,66 emulsion-droplet coalescence,55,63 spray drying,67 
sieving,63 coacervation/precipitation,63,66,68 and ionic gelation.65,66,69-71 Methods such as 
emulsion cross-linking and emulsion-droplet coalescence involve the use of a harsh 
crosslinking agent that may induce an unnecessary chemical reaction with the active 
agents. Spray-drying and sieving produce relatively large microparticles, with diameters 
of approximately 1–10 µm and 543–698 µm, respectively.63 
Watzke and Dieschbourg conducted some of the earliest work on preparation of 
nanoparticles by covalent crosslinking.72 They prepared chitosan/silica nano-composites 
by simply reacting tetramethoxysilane with the hydroxyl on the chitosan polymer.72 At 
that point, nanoparticle delivery systems were not yet used to encapsulate 
pharmaceutically active agents (i.e., drugs).61 Ohya et al. were the first to present data 
using chitosan nanospheres for drug delivery applications.60 They used a water-in-oil 
emulsion method by crosslinking the amino groups of the chitosan with glutaraldehyde to 
produce nanospheres loaded with 5-fluorouracil, an anticancer drug.58,60,61,73 Both of 
these studies demonstrated the preparation of nano-sized particles that can entrap and 
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deliver drugs.60 The later discovery of glutaraldehyde's negative impact on cell viability 
and the integrity of the entrapped drug led to interest in less harsh preparation 
methods.60 Ionic gelation is an example of a more benign preparatory method for 
preparing chitosan nanoparticles. 
When chitosan, which is cationic, comes into contact with an anionic compound, it 
exhibits a unique feature, transitioning from liquid to gel in a process known as ionotropic 
gelation.60,61 The first reported case of using ionic gelation for drug encapsulation using 
TPP as the crosslinker was that of Bodmeier et al.60,74 This liquid-to-gel process (i.e., 
gelation) is due to inter- and intramolecular crosslinkages between tripolyphosphate 
(TPP) phosphates and chitosan amino groups.60,61 Their aim was to produce chitosan–
TPP beads; however, the results were nanoparticles.60,74 
After the Bodmeier findings, other groups used ionic gelation with TPP as the 
crosslinker for preparing particles. Shirashi et al. encapsulated indomethacin, an acidic 
drug, into chitosan gel beads.75 Calvo et al. looked at encapsulating protein into chitosan 
nanoparticles.76 Gan et al evaluated the potential of chitosan nanoparticles for delivering 
gene or protein macromolecules.77 Dung et al examined the potential for encapsulating 
oligonucleotides.78 Other groups have used ionic gelation to prepare insulin-loaded 
chitosan nanoparticles.79,80 
The ionic gelation method has been explored to encapsulate many different 
biomolecules and drugs, but the linkages between the chitosan and TPP are somewhat 
weak. To asses this weak linkage, Shu et al explored a novel approach to improving the 
mechanical strength of chitosan beads.81 Xu et al later examined different formulations 
of chitosan nanoparticles prepared by ionic gelation, assessing the effects of the 
molecular weight and deacetylation degree of chitosan, the concentration of chitosan, 
and the initial protein concentration.82 
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Ionic gelation is a novel method for preparing chitosan particles, and it offers clear 
advantages over other methods. Some of those advantages are its simplicity, fast 
production process, and freedom from a requirement for complicated equipment. In 
addition, ionic gelation relies not on chemical crosslinking but on reversible physical 
crosslinking by electrostatic interaction, which reduces the likelihood of the particles' 
introducing toxins or causing other undesirable effects. The ionic gelation method also 
offers the flexibility of producing either microparticles or nanoparticles.83,84 
Despite the significant advantages of the ionic gelation method and the importance 
of particle size in determining drug-delivery characteristics, definite formulation 
parameters for producing particles of a specific size range have yet to be defined. In 
previous work, researchers looked at only one preparatory variable at a time and did not 
undertake a systematic look at all the preparatory variables simultaneously. The second 
aim of this dissertation addresses that gap. Our model drug for encapsulation was 
doxycycline, a commonly prescribed, inexpensive, broad-spectrum antibiotic.85 In our 
previous work, we demonstrated that encapsulation of doxycycline into chitosan particles 
can improve drug delivery and the efficacy of the antibiotic while minimizing adverse 
effects.86 The objective of the research was to undertake a systematic study of ionic-
gelation preparatory variables and their influence on particle size and morphology. Sixty-
four different combinations of chemical constituents and procedural steps were used to 
generate chitosan nanoparticles of wide-ranging morphology and size. A series of 
multivariate linear models was constructed to determine the optimum (i.e., most 
influential) variables for determining particle size. These findings can lay the groundwork 
for not only understanding but also controlling particle size. 
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2.4. Doxycycline 
Doxycycline is an inexpensive, semi-synthetic antibiotic commonly used as a broad-
spectrum drug to treat both intracellular and extracellular bacterial infections. Commonly 
targeted pathogens include both aerobic and anaerobic gram-positive and gram-
negative bacteria and also other microorganisms such as protozoa, mycoplasma, 
mycobacteria, and spirochetes.85,87,88 Due to doxycycline's antibacterial effects on a wide 
range of pathogens, it is currently one of the most commonly prescribed antibiotics 
worldwide for treating infectious diseases such as pelvic inflammatory disease (PID), a 
polymicrobial infection.85,89  
For the treatment of diseases such as PID, the CDC recommends 200 mg of 
doxycycline to be administrated orally or intravenously every 12 hours.15 When 
administered orally or intravenously, however, doxycycline may cause esophageal 
ulcers, gastrointestinal irritation, and local inflammation, which may in turn lead to 
premature cessation of treatment.90-93 Furthermore, the use of doxycycline may result in 
mechanical scarring of tissues and cavities in the body, as well as blood vessels.94-98  
In recent years, drug encapsulation and delivery via small particles has garnered 
increasing interest. Encapsulation may help prevent adverse effects by protecting 
sensitive tissues from fast drug exposure while also improving drug efficacy by achieving 
slow, sustained release directly at the infection site. Having patients complete the entire 
treatment cycle would also increase the likelihood of complete pathogen elimination. 
These properties suggest that encapsulation of doxycycline into biodegradable 
nanoparticles could perhaps be used to eventually improve treatment of PID via direct 
transcervical drug delivery. 
We investigated chitosan nanoparticles as a potential carrier of doxycycline. The 
goal was to undertake an initial assessment of particle properties relevant to 
 15 
encapsulated drug delivery through a localized (i.e., transuterine) route. We are hoping 
that introducing doxycycline–chitosan nanoparticles to the reproductive lumen will 
produce sustained drug levels in the reproductive tract by adhesion of the particles to the 
mucosa as well as absorption of the particles into the tissue, thus increasing the 
likelihood of complete pathogen elimination. We created and then characterized 
doxycycline-loaded chitosan nanoparticles (DCNPs) in terms of their morphology (size 
and shape), drug encapsulation efficiency and release rates, in vitro antibacterial activity, 
and in vitro cytotoxicity.  
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Chapter 3 - Design of a Novel Sterile Uterine Sampler Cover Device 
 
In this chapter, the design and development of a novel sterile uterine sampler cover 
(SUSC) device to collect sterile cell samples from the fallopian tubes, uterus, and 
surrounding areas is presented to improve the accuracy of diagnosis of pelvic 
inflammatory disease (PID). This device is designed to collect sterile samples from the 
uterus that can be then analyzed to identify the specific pathogens causing PID as well 
as other uterine infections. The proposed device can also be used to deliver nano-
encapsulated drugs at the site of infection for targeted drug delivery. 
 
3.1. Background 
As described previously in Section 2.1, endometrial sampling devices and/or 
techniques are currently available but none of these devices and/or techniques can 
procure sterile specimen samples from the endometrium and surrounding areas. 
Procuring sterile specimen samples is expected to provide an accurate diagnostic of PID 
and to increase understanding of the normal flora in asymptomatic women.  
The SUSC device proposed in this research will enable the collection of 
uncontaminated endometrium samples through the vagina to increase understanding of 
the natural microbial ecology of the uterus. The collected samples can be later analyzed 
to identify the specific pathogens causing PID and to determine adequate treatment 
methods. The SUSC device can also be used for addressing other gynecological 
disorders/problems such as removal of obstructions in the fallopian tubes, targeting 
sperm delivery and delivering MEMs technology containing diagnostic agents for 
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sensitive imaging of neoplastic cells in the fallopian tubes and monitoring the normal 
flora of the fallopian tubes and the uterus. 
The following sections present the device design and development that include 
users’ requirements, engineering specifications, device design, prototyping, analysis, 
and validation. 
 
3.2. Materials and Methods 
The SUSC device was developed using a formal design process commonly used in 
medical device development. This formal process began with a discussion of end-user 
requirements, which led to the corresponding engineering specifications, design concept 
generation and selection, engineering analysis, device fabrication and validation. 
3.2.1. End-User Requirements 
A thorough literature review was conducted in combination with a clinician survey 
(Appendix A) to gather user requirements for a device to collect sterile samples from the 
uterus. The survey consisted of five short questions that focused on identifying the 
needs and their importance to determine the specifications of the device. These end-
user requirements included: ease of handling; comfortable (to the patient); prevents 
sample contamination; device durability; and dimensions of the device. The resulting 
end-user requirements are listed in Table 3-1 in descending order of importance. The 
importance of each end-user requirements were ranked based on the information 
gathered from the survey.  
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Table 3-1: End-User requirements with description of each requirement. 
 
 
 
 
 
 
 
 
3.2.2. Anatomical Design Constraints 
The end-user requirements (Table 3.1) were analyzed and converted to engineering 
specifications. The SUSC device is designed to enter through the vagina. At the distal 
end of the vaginal canal, the device enters the uterus through the narrow cervical 
opening. Therefore, we analyzed the female reproductive system to collect the 
dimensions and constraints for device specifications. These dimensions vary from 
woman to woman depending on age and hormonal state; thus the device must 
accommodate the range of female measurements. 
The vagina, where the device enters the body, is connected to the cervix of the 
uterus (womb). Extending from either side of the uterus are the fallopian tubes, and at 
the ends of the fallopian tubes are the ovaries, two small almond-shaped organs (Figure 
3-1). The fallopian tubes are two thin tubes 80 to 120 mm in length on either side of the 
uterus that serve as the pathway during ovulation for the egg leaving the ovary to reach 
the uterus for fertilization. The human vagina is a long, collapsible fibromuscular tubal 
organ with a length of 60 to 120 mm measured posteriorly. This length varies depending 
on the age of the female as well as her state of sexual arousal.  
Requirements Descriptions 
Prevent Contamination Prevents vaginal and cervical 
contamination from entering the uterus 
Patient Comfort Causes little to no pain during the 
sampling process 
Ease of Handling It is easy to handle 
Device Durability Device is stiff enough so that it does not 
bend easily but soft enough that no harm 
is done to the patient 
Dimensions of Device It is able to be used in cervices of different 
size  
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Figure 3-1: Schematic representation of the vagina, cervix, uterus, fallopian tubes, and 
ovaries. 
 
At the top end of the vaginal tube is the cylindrically shaped cervix, and at the center 
of the cervix is an opening known as the external orifice (commonly referred to the as 
"external os"). The portion of the cervix projecting into the vagina is known as the 
ectocervix and is approximately 30 mm long and 25 mm wide; the dimensions vary 
depending on age and hormonal state. The spindle-shaped endocervical canal, in the 
cavity of the cervix, is the passageway between the external os and the uterine cavity; it 
also varies in width and length. Women of reproductive age have the widest 
endocervical canals (7–8 mm). The endocervical canal terminates at the internal orifice 
("internal os") to the uterine cavity. 
If the uterus is cut transversely (Figure 3-2) from the entrance of the left fallopian 
tube to the right one (A-A’) it measures from 26 to 34.6 mm. From the top of the uterine 
cavity to the internal os (D-D’) is 33.2 to 43.8 mm. Going down one-third from the 
superior portion of the uterine cavity (B-B’) is 17.3 to 27.5 mm and then going down 
Uterus'
Ovary'Ovary'
Vagina'
Fallopian'Tubes'
Cervix'
Internal'Os'
External'Os'
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another one-third (C-C’) it is 10 to 18.6mm. These dimensions of the endometrium are 
documented in Chien.99 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2: Transverse view and dimensions of the endometrium (uterus). 
 
In addition to those dimensional constraints, the positioning of the uterus imposes 
another constraint. The uterus is normally found in the anteverted position so it is tipped 
forwards. In a few cases, it is retroverted in the position so it is tipped backwards. The 
different possible positions of the uterus are illustrated in figure 3-3.  
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 21 
 
 
 
 
 
 
 
 
 
 
Figure 3-3: Illustration of the different positions of the uterus. 
 
The SUSC device was designed to enter through the vagina, which varies in length 
from 60 to 120 mm. At the distal end of the vaginal canal, the SUSC device enters the 
uterus through a 2-3 mm cervical opening. These dimensions vary from woman to 
woman depending on age and hormonal state. Therefore, the device must 
accommodate the range of female measurements. Figure 3-4 illustrates the different 
sizes of the uteruses in different woman at different hormonal stages.   
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Figure 3-4: Illustration of the uterus at different age groups. 
 
3.2.3. Concepts Generation/Selection and 3D Model Development 
After end-user requirements were established, the possible range of device functions 
was narrowed to two primary aims. The first function of the device is to collect sterile 
specimen samples from the uterus while preventing vaginal and cervical contamination. 
The second function is to deliver nanoencapsulated drugs directly to the uterus. Once 
these primary functions were established, various design concepts were brainstormed 
and studied. The top three concepts were then evaluated in detail and weighted values 
were assigned to each end-user requirement and/or function (Table 3-2).  
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Table 3-2: Detailed evaluations of the top three design concepts arising from the initial 
brainstorming and preliminary evaluations. The weighted percentage was determined by 
a survey administered to a group of Physicians. 
 
 
 
 
 
 
For the straight single cannula sampler (concept A in Table 3-2), the entire design 
was a single and straight sampler with an exit hole on the tip of the cannula. The major 
drawback of this concept was the lack of proper prevention of vaginal and cervical 
contamination during sampling. In addition, the straightness of this design concept 
posed another problem. Because the uterus is normally positioned anteverted, insertion 
of a straight device would have a strong possibility of causing tissue damage. 
Furthermore, having the exit hole at the tip of the sampler may result in blockage by 
tissue thus obstructing the sample collection.  
The concept of rounded two-sided sampler (concept B in Table 3-2) was also 
explored. In this design concept, there were two tubes in one barrel. The barrel has two 
 
Concepts 
A-Straight One-Sided 
Sampler 
B- Rounded Two-
Sided Sampler  
C- One-Sided Sampler 
with Cover  
Selection Criteria/ 
(Weight) 
Rating Weighted 
Score 
Rating Weighted 
Score 
Rating Weighted 
Score 
Prevent Contamination 
(40%) 
1 0.08 2 0.16 5 0.4 
Patient Comfort 
(26%) 
3 0.156 2 0.104 4 0.208 
Ease of Handling 
(18%) 
4 0.144 2 0.072 4 0.144 
Device Durability 
(10%) 
3 0.06 4 0.08 3 0.06 
Dimension of Device 
(6%) 
4 0.048 1 0.012 4 0.048 
Total Score 0.488 0.428 0.86 
Rank 2 3 1 
Continue? No No Yes 
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exit holes that are in opposite direction to allow the inner tubes to emerge for sample 
collection. The two inner tubes provide dual functionality: suctioning uterine tissue 
specimens and delivering therapeutic drugs directly to the uterus. The tip of the barrel is 
rounded to diminish the likelihood of potential tissue damage during insertion. Putting the 
holes on the side of the device addressed the problem with tissue blockage (as in 
concept A) upon insertion. Because of the complexity of the internal design, the outer 
diameter of the barrel would be larger than the single cannula design (concept A). 
Therefore, this design has a greater potential for causing patient discomfort. In addition, 
the device does not completely address the prevention of contamination during uterine 
specimen sampling. 
The concept of an outer cannula with a protective cover (concept C in Table 3-2) was 
also explored. This approach addresses the major problem of contamination, which the 
other two concepts did not address satisfactorily. The protective cover serves as an 
outer covering to help prevent the spread of contamination from the vagina and uterus. 
The outer cannula would provide additional protection from contamination. This design 
concept has a 20° angle at the distal end of both cannulas, designed to allow the device 
to follow the normal curvature of the uterus. This overall concept allows for easier 
insertion and higher prevention of cross contamination.  
After evaluation of the designs, concept C was selected for development. Based on 
the dimensional constraints of the female reproductive system and the proposed function 
of the device, the device should consist of three components: a sterile cover, an outer 
cannula, and a sampler. These three components were selected for the final design 
placing a high priority in preventing contamination while minimizing the outer diameter of 
the device to reduce any form of pain during insertion. When all three components are 
assembled, the device's maximum length and diameter should be at least 420 mm and 
at most 5 mm, respectively. This length ensures its ease of use and maximum distance 
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from the patient’s vaginal area to the external working area. An outer diameter of 5 mm 
is the absolute maximum to ensure little to no patient pain. The diameter of the sampler 
should not be greater than 2.5 mm. Table 3-3 summarizes the engineering specifications 
based on the dimensional constraints imposed by the female anatomy. 
 
Table 3-3: Engineering specifications for each component of the SUSC device. 
 
Part(s) Function Dimensions 
Outer Cannula Housing for the sampler  Length = 200 mm 
Outer diameter = ˂5.mm 
Diameter of hole = ˂3.mm 
Sampler  Collect tissue sample and/or to 
deliver drugs 
Length= 240 mm 
Diameter= ˂2.5 mm 
Sterile Cover Protective covering of the 
device 
Length= ˂180 mm 
 
3.2.4. Engineering Finite Element Analysis 
Once a design concept was selected and a detailed Solidworks CAD model was 
developed, finite element analysis (FEA) was used to analyze the design, guide the 
selection of construction materials, and identify potential failure design points. The 
amount of bending and deformation of the outer cannula and sampler under stress 
and/or applied load was analyzed. 
 
3.2.5. Concept Validation 
After the failure points of the design model were identified and the design was 
adjusted, a physical prototype was developed to test the device's primary function: ability 
to collect sterile uterine samples. The device was named sterile uterine sampler cover 
(SUSC). The SUSC device was fabricated using polyethylene tubing for the outer 
cannula, a current endometrium sampler, and latex finger cot for protective cover. The 
prototype was tested using a Luria-Bertani (LB) agar test. In a test tube, there were two 
layers of LB agar, the bottom layer was sterile and the top layer was enriched with 
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Escherichia coli (ATCC 25922). Then, 8 mL of LB agar media was placed in four 15 mL 
BD Falcon tubes (BD Biosciences), and then allowed to solidify at room temperature. 
Next, each tube was inoculated with 1.0×105 colony-forming units (CFUs)/mL of 
Escherichia coli cells before one hour of incubation at 37°C.  
The fabricated prototype device was then used to collect an agar sample from the 
sterile bottom layer within the test tube. The collected sample was released into another 
tube containing 4 mL of sterile LB broth. This tube was then incubated at 37°C under 
light agitation for an hour. After the incubation period, 500 µL of the liquid culture was 
analyzed at OD600 and the number of bacterial cells was calculated. Then, a 100-µL 
sample of the liquid culture was plated in triplicate on LB-agar plates incubated at 37°C 
overnight. The controls were as follows: (1) a swab of bacteria from the contaminated 
layer, (2) sampling with only the sampler and (3) sampling with the sampler passing 
through the outer cannula without the finger cot. The rationale behind this test was to 
ensure that the SUSC device could collect a sample of the sterile bottom-layer agar 
despite passing through the highly contaminated environment of the upper agar layer. 
3.3. Results and Discussion 
3.3.1. Design Concepts and Prototypes 
The SUSC device prototype was designed and analyzed based on the outer cannula 
with a protective cover (concept C, table 3-2) design. This prototype device has three 
main components: an outermost protective cover, an outer cannula, and a sampler 
(figures 3-5, 3-6, and 3-7). The outermost protective cover, made of latex, can be 
stretched to a maximum length of 180 mm to give maximum elastic stretch at the tip of 
the outer cannula, thus making it easy to break by the sampler just before sampling. The 
outer cannula, which houses the sampler, has an outer diameter of 5 mm, an inner 
diameter of 3 mm, and a wall thickness of 2 mm. On the top of the outer cannula is a 3-
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mm in diameter exit hole for the sampler to pass through to collect the samples. The 
sampler is 240 mm in length, 2.5 mm in diameter, and has a wall thickness of 1 mm. 
There is a 1-mm diameter hole on the side of the distal tip of the sampler. Tissue 
samples are drawn through this hole and into the sampler by using the attached plunger 
to create a vacuum. Each component of this SUSC device, with the exception of the 
outer protective cover, has a 20° angle at each end to facilitate insertion through the 
vagina. This design satisfies the engineering specifications: the end-user requirements 
for the design along with all the anatomical constraints of the female anatomy were 
addressed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5: The CAD image of the SUSC device.  
Outer Cannula 
Plunger of Sampler 
Cover 
Lock Hinges 
Lock  
Sampler 
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Figure 3-6: The CAD images of the SUSC device showing three different phases. (a) 
Assembling of the SUSC device (b) the sterile cover stretched and locked in position on 
the outer cannula and (c) the cover in its retracted position after piercing with the 
sampler.  
(c) 
(b) 
(a) 
Rolling protective cover 
onto the outer cannula 
After locking the cover onto the outer the 
sampler is then used to pierce the cover 
After deployment of the 
sampler the cover retracts 
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Figure 3-7: The dimensions of the SUSC device.  
200 mm (length of outer cannula) 
240 mm (length of model sampler) 
5 mm (outer diameter of outer cannula)  
3 mm ( inner diameter of the outer cannula) 
Top view of lock with 
5.2 mm inner diameter 
Bottom view of lock 
with showing slots for 
locking hinges 
Slots for locking hinges 
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3.3.2. Deformation and Stress Distribution 
To simulate insertion of the device into the vagina, a 1N force was applied to the 
device components, and the resulting bending and deformation was measured. The first 
simulation was for testing the potential bending of the outer cannula during insertion in 
the vagina. The second simulation was for testing the ability of the sampler to break the 
stretched protective cover on the outer cannula before sampling. Figure 3-8(a) shows 
the stress distribution after applying a 1-N force to the external end (the end not being 
inserted into the vagina) of the outer cannula made of a low-density polyethylene (PPE). 
This simulates the force applied on the outer cannula by the stretching of the protective 
cover. Figure 3-8(b) shows the results for a 1-N force applied to the sampler to simulate 
the force associated with breaking the protective cover. 
The red areas indicate the most stressed areas while the blue areas are the least 
stressed. For this particular simulation, the outer cannula experienced no areas of critical 
stress (the image shows no red areas). On the other hand, the tip sampler, which is 
used to break the protective cover, is under critical stress, evidenced by the red areas. 
Still, the component was not deformed. Therefore, both the outer cannula and sampler 
are expected to withstand the forces caused by stretching the protective cover and 
breaking the protective cover. In both cases, the yield strength (the stress which the 
material deformed plastically) of the low-density polyethylene was 6,894,757.3 N/m2. 
Based on the applied force, the maximum stress for the outer cannula was 404,763.1 
N/m2; for the sampler, 13,163.3 N/m2.  
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Figure 3-8: The FEA images illustrating the stress distribution. A 1-N force was applied 
to (a) outer cannula and (b) sampler with low-density PPE as the test material. 
 
3.3.3. Device Operation and Sterile Sampling 
This medical device should be used only by licensed gynecological healthcare 
providers in a sterile clinical setting. Following are the proposed steps for operating the 
SUSC (Figure 3-9): The lubricated sterile protective cover is pulled toward the operator 
and locked so that it covers the cannula completely. The SUSC device is then inserted 
through the vagina through the previously cleansed cervix until it reaches the internal os. 
Given the diameter of the cannula, there will be resistance at the internal os and this 
location will be clearly felt by the user. Once the cannula is positioned at the internal os, 
the protective cover is stretched on the body of the outer cannula and the sampling 
device is advanced until the protective cover breaks and retracts to the lock, outside the 
vagina. The sampling device can then enter into the uterus for endometrial collection. 
The sampling device is then removed from the uterus and the specimen is deposited into 
sterile media for culture or genetic analysis.  
Sampler tip (used for  breaking 
the outer protective cover) 
1 N force (to stimulate the 
force used to break protective 
cover) is applied at this end 
(b) 
1 N force used to insert 
device is applied at this end 
Outer Cannula Tip (with 
suction cannula exit hole 
on top) 
(a) 
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Figure 3-9: Illustration of the operation of the SUSC device. (a) SUSC insertion with 
protective cover in the lock position on the outer cannula, and (b) sampler deployment 
and protective cover retraction. 
 
The SUSC device and three different sampling methods were tested to analyze the 
effectiveness of the device. These three sampling methods were: use of a swab, use of 
a sampler only, and use of a sampler inside an outer cannula. When using the different 
approaches to sample a sterile agar layer confined beneath an upper contaminated 
layer, the SUSC device resulted in much lower sample contamination as shown in 
Figure 3-10. Compared to a swab from the contaminated layer (100% contamination), 
using a bare sampler to penetrate the upper layer and sample the lower sterile layer 
resulted in a 27% reduction in contamination. Using a sampling device in an outer 
cannula (no protective cover) resulted in only a 7% reduction in contamination. In 
contrast, sampling with the SUSC device resulted in 92% reduction in contamination. 
(a) (b) 
Internal Os 
External Os 
Cover 
Lock  
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These percentages were obtained by analyzing liquid cultures using optical density at 
600 (OD600). It is believed that the level of contamination on the sample, although 
minimal, could be the result of human error during sampling and that further practice in 
using the device would help to decrease this contamination. Compared to the plate 
streaked with a sample of the contaminated layer (Figure 3-11(a)), the plates streaked 
with samples from the sampler only (Figure 3-11(b)) and the suction device in the outer 
cannula with no protective covering (Figure 3-11(c)) show similar confluent bacterial 
overgrowth. On the other hand, only a few isolated colonies were observed on the plates 
streaked with samples from the SUSC device as shown in Figure 3-11(d). 
 
 
 
 
 
 
 
 
 
 
Figure 3-10: Specimen contamination resulting from various techniques used to sample 
a sterile agar layer confined beneath a contaminated upper layer.  
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Figure 3-11: LB-agar culture plates for samples collected from a sterile agar layer 
confined beneath a contaminated upper layer. Collection techniques: (a) no technique; 
swab from the E. coli–contaminated upper layer, (b) sampler only, (c) sampler in outer 
cannula (no protective covering), and (d) the proposed SUSC device. 
 
3.4. Summary 
In this chapter, a single-use sterile uterine sampler cover (SUSC) device for 
collection of uncontaminated uterine specimen samples for a more accurate diagnosis of 
PID and other endometrial infections was presented. The SUSC device consists of three 
components: an outermost protective cover, an outer cannula, and a sampler. The 
protective cover of the SUSC device aims to protect the device during insertion through 
the naturally contaminated vagina and cervix for the collection of uterine specimens. The 
main advantage of the presented device is that its protective cover and sterile technique 
can be used with any currently available endometrial sampler with an outer diameter of 
up to 3mm, such as the Pipelle, Explora curette or select cell©. Once the SUSC device is 
in place, a delivery cannula could be inserted into the uterus for delivery of nano 
encapsulated drugs to the uterine cavity for treatment of infection. The next chapter will 
(a) 
(c) (d) 
(b) 
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present the analysis of twelve selected preparatory variables of the ionic gelation 
method for encapsulating an antibiotic into chitosan nanoparticles. These antibiotic-
loaded chitosan nanoparticles can then be transvaginally delivered using the SUSC 
device for potential treatment of PID.  
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Chapter 4 - Analysis of Preparatory Variables Relevant to Chitosan Particle Formation 
by Ionic Gelation 
 
This chapter presents a systematic study of the preparatory variables of the ionic 
gelation method and their effect on the chitosan particles' characteristics. In the study, 
multivariate analysis is used to determine the optimum model of preparatory variables 
that influence particle size. The variables selection was performed using multiple 
regression analysis through two methods: Akaike’s information criterion (AIC) and F-
statistics/p-value selection methods. This optimal model can increase understanding of 
particle size formation using the ionic gelation method to enable mass production of 
particles of desired size for drug delivery systems. 
 
4.1. Background 
Chitosan particles have been extensively explored as a promising drug delivery 
system due to their muco-adhesive property, which is of great value for delivering 
particle-encapsulated drugs to intracellular sites. As described in Chapter 2, the ionic 
gelation method is one of the most commonly used methods for preparing these 
particles. However, previous work only studied one preparatory variable at a time, and 
did not provide a systematic analysis of all the preparatory variables at once. The aim of 
this study is to identify the most relevant methodological parameters in determining 
chitosan particle size to control particle formation for particular delivery systems. 
The particles were characterized in terms of their morphology and particle size 
distributions. Two statistical selection methods were applied to these data to build an 
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optimal model: Akaike’s information criterion and F-statistics/p-values selections. These 
statistical analyses were used to identify preparatory variables that were statistically 
significant in determining the average diameter of the chitosan particles. The analysis of 
the preparatory variables lays the groundwork for a better understanding of chitosan 
particle size variation when synthesized by the ionic gelation method. This can 
potentially lead to better control of particle size formation to enable the mass production 
of chitosan particles using the ionic gelation method for specific drug delivery systems. 
 
4.2. Materials and Methods 
4.2.1. Materials 
Chitosan powders (deacetylation of 75%) were obtained from Sigma Aldrich (USA). 
Sodium tripolyphosphate (TPP) powder was supplied by Sigma Chemical Company 
(USA). Doxycycline, phosphate buffered saline (PBS), and acetic acid were obtained 
from Fisher Scientific (USA). All other chemicals were of analytical grade and were 
obtained from a variety of vendors. 
 
4.2.2. Preparation of Chitosan Nanoparticles 
Chitosan particles were prepared using the ionic gelation method of Clavo et al.70 
The basic procedure entailed mixing the polymer with a crosslinker to prepare blank (no-
drug) particles. For drug-loaded particles, doxycycline was added to the mix as shown in 
Figure 4-1. Sixty-four different formulations that consisted of different combinations of 
chemical constituents and procedural steps were used to create the chitosan particles 
(table 4-1). In earlier experiments done by our group, the effect of using a wider range of 
acetic acid concentrations (0.25M, 0.50M, and 0.75M) to dissolve the chitosan powder 
was also evaluated. 
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Figure 4-1: Schematic representation of the variables involved in the overall process for 
preparing chitosan nanoparticles. 
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Table 4-1: List of variables and values used in the formulation of the chitosan 
nanoparticles. 
 
 
Chitosan solution was prepared by dissolving the chitosan powder—10 kDa or 60 
kDa (Table 4-1, variable X1)—in acetic acid or water (X3) for a final concentration 
(variable X2) of 0.1% or 0.2% weight by volume (w/v). This solution was magnetically 
stirred at 400 rpm at room temperature and allowed to protonate for 1 hour or 24 hours 
(variable X4). The cross-linker, sodium tripolyphosphate (TPP), was prepared by 
dissolving it in acetic acid or water (X6) to achieve final TPP concentrations ranging from 
0.21% to 0.84% w/v (X5). The various combinations of chitosan and TPP concentrations 
produced three different chitosan:TPP ratios (X9): 1:1, 1:2, 1:3, 1:4, 1:5, 1:8, 3:1, and 
6:1. 
Some particles were prepared as blanks that contained no drug, and other particles 
were prepared to encapsulate the model drug, doxycycline (Table 4-1, variable X7). 
Doxycycline stock solution (200 mg/mL) was prepared by dissolving doxycycline powder 
Variable Symbol Values 
Chitosan Type X1 10 kDa 60 kDa 
Chitosan Concentration X2 0.1 w/v% 0.2 w/v% 
Chitosan Dissolving Solution X3 Water Acetic Acid (0.25M) 
Chitosan Protonation Time X4 1 hour 24 hours 
TPP Concentration X5 0.21w/v% 0.42w/v% 0.60w/v% 0.75w/v% 0.84w/v% 
TPP Dissolving Solution X6 Water Acetic Acid (0.25M) 
Drug  X7 Doxycycline  None 
Order of Combination X8 Chitosan + Doxy + TPP TPP + Doxy + Chitosan 
Chitosan: TPP Ratio X9 1:2 1:4 1:6 
Synthesis Time X10 1 hour 2 hours 24 hours 
Centrifugation X11 Yes No 
Wash/Reconstitution Solution X12 Water PBS 
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in nanopure water. To initiate ionic gelation (particle formation), the chitosan, TPP, and 
drug solutions were combined (Figure 4-1). Blank nanoparticles were formed by 
dropwise addition of TPP to a chitosan solution that was being magnetically stirred. 
Drug-loaded particles were formed by dropwise addition of 100 µL of doxycycline to the 
chitosan solution before dropwise addition of TPP, or by dropwise addition of 
doxycycline to a stirred TPP solution before dropwise addition of chitosan (variable X8). 
The blank and drug-loaded solutions were allowed to synthesize particles for 1, 2, or 24 
hours (X10) under magnetic stirring at room temperature. The particles were then 
collected and were centrifuged at 10,000 rpm for 5 minutes or were allowed to 
precipitate at room temperature until supernatant is clear and pellet is obvious (X11). The 
resulting pellet or precipitate was then washed and resuspended in either nanopure 
water or phosphate buffered saline, PBS (X12). 
 
4.2.3. Physical Characterization of Nanoparticles 
Particle size distributions were determined with a Microtrac Particle Size Anaylzer 
(measures particles sizes from 0.8 to 6500 nanometers), which measures dynamic light 
scattering by particles. All analyses were performed on samples diluted in 1 mL nano-
pure water. Morphology of the chitosan nanoparticles was examined using a JEOL 1400 
transmission electron microscope (TEM). TEM samples were prepared by placing a drop 
of resuspended nanoparticles (blank or drug-loaded) onto a formvar-coated copper grid 
that was allowed to dry before TEM analysis.  
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4.2.4. Variable Selection 
To quantitatively assess and determine which of the twelve preparatory parameters 
(table 4-1) had the greatest influence on particle size, a series of multivariate linear 
models were constructed. Multivariate linear regression modeling is an approach used to 
model the relationship between a dependent variable and several independent 
variables.100 The models were then ranked using Akaike Information Criterion (AIC) and 
F-statistics/p-value methods. Both methods are independent from the distribution of the 
variables; in other words, both work well for normal and non-normal data distributions. 
The twelve preparatory variables investigated, Xn, are listed in table 4-1; average particle 
diameter, Y, was the dependent variable. All statistical analyses were performed using 
MATLAB (version 2009b). 
The AIC selection approach builds the simplest possible optimal model to explain 
observed variation in an experimental outcome,101-104 which in our case is the mean 
particle diameter Y. The method performs stepwise selection of significant preparatory 
variables through forward addition based on the AIC value, which measures how much 
variation in outcome, Y, can be accounted for by each individual variable. AIC considers 
the number of observations (n); the number of explanatory variables (K) and the residual 
sum of squares (RSS) for each model and the AIC value is calculated based on equation 
1.102,103 
 
The F-statistics/p-value variable-selection method, like the AIC-based method, also 
builds an optimal model based on the empirical data set—identifying those variables that 
exert the greatest influence on particle diameter—but does so by selecting variables with 
significant p-value for the final model. This non-parametric, permutation-based method 
assesses each variable's statistical significance and its influence on the variation in the 
(1) AIC = n!loge(RSS/n) + 2K 
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outcome, Y, before selecting it to the final model. Variables are sequentially added by 
selecting the variable that yields the largest partial F-statistic with significant p-value and 
corresponding adjusted R2.102 To test the significance of each variable in the model, an 
F-statistics test was performed using a level of significance, alpha (α), of 0.05. 
Conditional tests were conducted for both selection methods to first examine the 
independent effect of each preparatory variable on mean particle diameter. For AIC-
based selection, the conditional test is used to select the order of variable entry into the 
final model. Marginal tests, in contrast to the conditional tests, examine the effect of 
each variable on Y after taking into account the effects of preparatory variables 
previously selected during the stepwise variable-selection procedure. 
 
4.3. Results and Discussion 
4.3.1. Statistical Selection of Influential Preparatory Variables 
The AIC-based variable-selection method identified four of the twelve variables as 
substantially contributing to variation of mean particle diameter (Y): chitosan-to-TPP ratio 
(X9), wash/resuspension solution (X12), synthesis time (X10), and TPP concentration (X5). 
Conditional testing was conducted first to assess the independent effect of each of the 
twelve preparatory variables and to select the first variable to enter in the final model 
(table 4-2). A variable's AIC value is of great importance because it expresses the 
strength of the variable’s influence on particle size variation: the smaller the AIC value, 
the more of the Y variation that is explained. Each variable has an AIC value, which is 
assigned a corresponding weight (Wts). The variable with the lowest AIC value was 
assigned a weight of zero and the remaining weights were scaled accordingly.  
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Table 4-2: Results of the conditional test using the AIC-based stepwise forward 
selection. Variables selected to be in the final model are shown in bold. 
 
Variables  AIC Wts R2 R2adj  
Chitosan:TPP Ratio, X9 952.4053 0 0.3105 0.2994 
Chitosan Type, X1  963.4904 11.0851 0.1802 0.1669 
TPP Concentration, X5 971.2121 18.8068 0.0750 0.0601 
Chitosan Concentration, X2  972.0659 19.6606 0.0626 0.0475 
Wash/Resuspension Solution, X12 972.3683 19.9630 0.0582 0.0430 
Chitosan Dissolving Solution, X3 972.8854 20.4801 0.0505 0.0352 
TPP Dissolving solution, X6 974.4036 21.9983 0.0277 0.0121 
Order, X8 975.5816 23.1763 0.0097 -0.0063 
Protonation Time, X4 976.0933 23.6880 0.0017 -0.0144 
Drug, X7 976.1125 23.7072 0.0014 -0.0147 
Synthesis Time, X10 976.1614 23.7561 6.6606e-04 -0.0155 
Centrifugation, X11 976.2040 23.7987 5.0692e-07 -0.0161 
 
Table 4-3 shows the variables selected for the optimal model selected by the AIC 
method. The variables selected for inclusion in this final model may not have had the 
lowest AIC values in the conditional testing of each individual variable (table 4-2) but 
together in the final model they resulted in the lowest cumulative AIC value (table 4.3). In 
this case, R2 values correlate well with the AIC values within the final model, which can 
explain 58% of the total variation in particle diameter.  
 
Table 4-3: List of variables selected for inclusion in the optimal model using the AIC-
based selection method. 
 
Variables AIC Wts R2 R2adj 
Chitosan: TPP Ratio, X9 952.4053 0.9958 0.3105 0.2994 
Wash/Resuspension Solution, X12 938.3569 0.8535 0.4652 0.4476 
Synthesis Time, X10 930.1306 0.7613 0.5461 0.5234 
TPP Concentration, X5 928.1074 0.2282 0.5761 0.5474 
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The F-statistics/p-value stepwise method selected the same four variables as being 
significant in contributing to variation in particle diameter for the optimal model (table 4-
4). As with the AIC-based method, conditional testing on each of the twelve variables 
was conducted first. The fact that both methods selected the same four variables for the 
optimal model (tables 4-3 and 4-4) is a strong indication of the significance of these 
variables in determining mean particle diameter. 
 
Table 4-4: List of variables selected for inclusion in the optimal model based on the F-
statistics/p-value selection method. 
 
Finally, the four selected variables were entered into a multiple linear regression 
model for the purpose of calculating the overall F-statistics/p-value and an R2 value to 
express the overall significance of the model. The resulting equation, equation two with 
coefficients for mean particle diameter (Y) was as follows: 
 
 
 
The ratio of chitosan to TPP, X9, was identified as the single most important variable 
(p=0.001) in determining mean particle size: the higher the ratio, the smaller the mean 
particle diameter. This variable explains 31% of the variation in particle size (as indicated 
by the partial R2 value of table 4-4). This finding—that the chitosan:TPP ratio plays a role 
in determining the size of the nanoparticles—is in agreement with the non-statistical 
Variables Partial F P Partial R2 Partial R2 adj 
Chitosan:TPP Ratio, X9 27.9262 1.0000e-03 0.3105 0.2994 
Wash/Resuspension Solution, X12 17.6342 1.0000e-03 0.1546 0.1410 
Synthesis Time, X10 10.7019 0.0030 0.0810 0.0661 
TPP Concentration, X5 4.1789 0.0500 0.0300 0.0144 
(2) Y = 6821 – 1520X9 – 1383X12 + 2.2X10 – 1715X5   
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work of Zhang et al,51 which concluded that particle sizes are dependent upon the 
chitosan-to-TPP ratios. 
The identity of the wash/resuspension solution, X12, was also identified by both 
selection methods as being significant (p=0.001). The addition of this variable to the 
model increased the overall R2 value from 31% to 47% (table 4-4). In other words, the 
two variables in the model thus far explain 47% of the variations in mean particle 
diameter, Y. The negative coefficient of this categorical variable indicates that one 
solution increases the particle size while the other decreases it. In this case, using water 
resulted in larger particle diameters while PBS produced smaller particles. 
The third significant variable selected for the final model was synthesis time, X10 (p= 
0.0030). As synthesis time increases, particle size also increases. Allowing more time for 
ionic-gelation synthesis may result in particle-to-particle linking. The last variable of 
significance selected for the regression model was the TPP concentration, X5 (p= 0.05). 
According to the model, increasing the TPP concentration results in smaller particles. 
Clavo et al.76 also reported that an increase in TPP concentration produces smaller 
particles. 
Overall, the linear regression model (equation 2) was found to be significant 
(p=0.001), indicating that the mean particle diameter and the set of selected variables 
are significantly related. The optimal model containing these four variables accounts for 
58% of the observed variation in mean particle diameter. Narrowing down the field of 
potentially influential preparatory variables from twelve candidates to four significant 
variables can lead to higher control of determining chitosan particle size.  
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4.3.2. Morphology and Particle Size Observations 
The acidity of the solution used to initially dissolve the chitosan powder exerts a 
profound influence on particle formation. The use of nanopure water produced particles 
with no well-defined borders and severe clumping (figure 4-2(a)). With 0.25M acetic acid, 
we saw nicely formed particles with more defined borders and with very little clumping 
(Figure 4-2(b)). When the concentration of acid was increased to 0.50M, the particles 
were slightly formed but were not as well defined as the particles prepared in the 0.25M 
acid. Moreover, there were signs of chitosan degradation (Figure 4-2(c)). At 0.75M, we 
saw degradation of chitosan so no particles were formed (Figure 4-2(d)). In summary, 
using an acetic acid concentration higher than 0.25M seems to impede the proper 
formation of nanoparticles. Pure water is also unsuitable. Acetic acid with a 
concentration of 0.25M seems to provide a workable environment for the formation of 
well-defined spherical particles. 
 
 
 
 
 
 
 
 
 
 
Figure 4-2: TEM images of blank (drug-free) chitosan particles prepared in (a) nanopure 
water, (b) 0.25M acetic acid solution, (c) 0.50M acetic acid solution, and (d) 0.75M acetic 
acid solution.  
0.5μm 
(a) 
0.5μm 
(c) 
2.0μm 
(d) 
2.0μm 
(b) 
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Centrifugation was not statistically selected as being significant in determining mean 
particle diameter, but quantitative observation using Nanotrac analysis indicated that 
centrifugation did affect particle size. Figure 4-3 shows the particle size distribution of 
centrifuged and precipitated samples. Note that the centrifuged sample resulted in 
predominately microparticles whereas the precipitated sample resulted in mostly nano-
sized particles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3: Particle size distributions of samples of drug-loaded particles. (a) passively 
precipitated and (b) centrifuged washed and resuspended in water.  
(b) 
(a) 
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TEM observations corroborated the conclusions drawn from equation 1 regarding the 
nature of the wash/resuspension solution. When particles were washed with nanopure 
water, centrifuged, and then resuspended in water, the resulting particle diameters were 
relatively large due to clumping of smaller particles (Figure 4-4). In contrast, particles 
washed, centrifuged, and then resuspended in PBS were uniformly spherical and 
individually distinct, as shown in Figure 4-5. 
 
 
 
 
 
 
 
Figure 4-4: TEM images of doxycycline-loaded nanoparticles that were washed, 
centrifuged, and then resuspended in nanopure water. (a) Several individual particles 
clumping together, 80kx magnification; (b) an agglomeration of smaller particles, 400kx 
magnification. 
 
 
 
 
 
 
 
 
Figure 4-5: TEM images of doxycycline-loaded nanoparticles that were washed, 
centrifuged, and then resuspended in PBS. Particle diameters range from approximately 
160 to 400 nm: (a) 6kx magnification; (b) 60kx magnification.  
(a) 
200nm 
(b) 
50nm 
2.0μm 
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4.4. Summary 
This study showed that chitosan nanoparticles (drug-loaded or drug-free) prepared 
by the ionic gelation method can be controlled by specific adjustments of the variables 
involved. The impacts of twelve preparatory variables on particle size were studied using 
two statistics stepwise forward selection methods. The results of both statistics selection 
methods showed that the ratio of chitosan to TPP, wash/resuspension solution, 
synthesis time, and TPP concentration contribute to 58% of the variation in determining 
the particle size when prepared using the ionic gelation method. All four selected 
variables were found to be significant (p=0.001) in contributing to the particle size. 
Therefore, this statistical selection of variables can be used to better understand the 
impact of variables on the particle size, and to improve the preparation of particles using 
the ionic gelation method.  
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Chapter 5 - Synergetic Effects of Doxycycline Loaded Chitosan Nanoparticles 
 
This chapter presents the synergetic effects of doxycycline-loaded chitosan 
nanoparticles. The doxycycline-loaded nanoparticles (DCNPs) were prepared using a 
modified ionic gelation method with tripolyphosphate (TPP) as a cross-linker. The 
DCNPs were characterized based on size and size distribution, morphology, drug-
release properties, antibacterial activity, and in vitro cytotoxicity.  Results show that 
encapsulating doxycycline into chitosan nanoparticles could facilitate intracellular and/or 
extracellular delivery of the drug and thus improve the drug efficacy in the treatment of 
bacterial infections. 
 
5.1. Background 
In recent years, drug encapsulation and delivery via small particles has garnered 
increasing interest. Encapsulation may help prevent adverse effects by protecting 
sensitive tissues from fast drug exposure while also improving drug efficacy by achieving 
slow, sustained release directly at the infection site. Having patients complete the entire 
treatment cycle would also increase the likelihood of complete pathogen elimination. 
These properties suggest that the encapsulation of doxycycline into biodegradable 
nanoparticles could be used to eventually improve treatment of PID via direct 
transcervical drug delivery. 
A detailed investigation of chitosan nanoparticles as a potential carrier of doxycycline 
to improve drug delivery and treatment efficacy was performed. Two particle 
formulations were examined: formulation DCNP6 containing approximately 1.5 times the 
 51 
crosslinker concentration of the other formulation named DCNP4. As a first step toward 
assessing this potential, we used an ionic gelation method to synthesize blank and 
doxycycline-loaded chitosan nanoparticles (DCNPs), which were characterized in terms 
of several properties relevant to clinical efficacy: particle size, shape, encapsulation 
efficiency, antibacterial activity, and in vitro cytotoxicity. 
 
5.2. Materials and Methods 
5.2.1. Materials 
Doxycycline, phosphate buffered saline (PBS), Millipore WST-1 Cell Proliferation 
Assay, and acetic acid were obtained from Fisher Scientific (USA). Sodium 
tripolyphosphate (TPP), fetal bovine serum, medium 199, and MCDB 105 medium were 
supplied by Sigma Chemical Company (USA). Partially (75%) deacetylated chitosan (60 
kDa) derived from shrimp shells was obtained in powder form from Sigma Aldrich (USA). 
All other chemicals were of analytical grade and were obtained from a variety of 
vendors. Eschericha coli (ATCC 25922) was purchased from American Type Culture 
Collection.  
 
5.2.2. Chitosan Nanoparticles Preparation 
The chitosan nanoparticles were prepared using the ionic gelation method of Clavo 
et al.57 Chitosan powder was dissolved, 0.2% weight by volume (w/v), in 0.25M acetic 
acid; this solution was magnetically stirred overnight at a speed of 400 rpm at room 
temperature. The acetic acid protonates the amine group of the chitosan molecule, for a 
more stable interaction with the crosslinking agent and the drug.59,105 The crosslinker, 
sodium tripolyphosphate (TPP), was prepared by dissolving the powder in 0.25M acetic 
acid at two different concentrations: 0.42% w/v (referred here as formulation 8, F8) and 
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0.60% w/v (formulation 10, F10). In a separate set of experiments, we examined 64 
different combinations of solutions and procedural steps, and identified these two 
formulations as consistently producing particles within a predictable formulation-specific 
size range. 
Blank nanoparticles were formed by combining the chitosan and TPP solutions for a 
total volume of 2 mL; the chitosan-to-TPP ratio was 23:1 for F8, and 16:1 for F10. To 
initiate ionic gelation (nanoparticle formation), TPP was added dropwise to the stirred 
chitosan solution, and the combined solution was then stirred for an additional hour. 
Blank nanoparticles prepared using F8 (0.42% w/v TPP) are here referred to as 
BKCNP4 while blanks prepared using F10 (0.60% w/v TPP) are referred to as BKCNP6. 
The solution with precipitated nanoparticles was centrifuged at 10,000 rpm for 5 minutes, 
and the resulting supernatant was saved for later analysis of its doxycycline content. The 
particles in the microcentrifuge tube were washed/resuspended by adding 2 mL 
nanopure water, and the tube was again centrifuged at 10,000 rpm for 5 minutes. The 
second supernatant was removed and discarded as preliminary tests had shown that the 
second supernatant contained no doxycycline residue. Finally, the particles were 
resuspended in 2mL nanopure water before further analysis.  
 A doxycycline stock solution was prepared by dissolving doxycycline powder in 
nanopure water to achieve a final concentration of 200 mg doxycycline per mL solution. 
Drug-loaded chitosan nanoparticles were then prepared according to the procedure 
outlined above, except that 100 µL of the doxycycline stock solution was added dropwise 
to the stirred chitosan solution just before the TPP addition. In every batch of DCNP 
solution, the final doxycycline concentration was 20 mg/mL. Drug-loaded chitosan 
nanoparticles prepared using 0.42% w/v TPP are here referred to as DCNP4; those 
prepared with 0.60% w/v TPP are referred to as DCNP6. All analyses of blank particles, 
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drug-loaded particles, and supernatant were initiated within 24 hours of particle 
preparation.  
 
5.2.3. Nanoparticles Characterization 
Particle size distributions for blank nanoparticles and DCNPs were determined with a 
Microtrac Particle Size Analyzer, which measures dynamic light scattering by particles in 
solution. The analyses were performed on samples of nanoparticles suspended in 1 mL 
of nanopure water. The shapes of the blank particles and DCNPs were examined using 
a JEOL 1400 transmission electron microscope (TEM) with a 0.38 nm assurance for 
point to point images and 0.2 nm for lattice images. Particles to be used for TEM 
examination were first dried under vacuum and stored in the dark at 4°C. TEM samples 
were then prepared by depositing a drop of nanoparticles onto a formvar-coated copper 
grid, which was allowed to dry by vacuum before TEM analysis. 
 
5.2.4. Encapsulation Efficiency 
Incorporation of doxycycline into the particles was characterized by measuring the 
doxycycline contained in the centrifugation supernatant. Since the total amount of drug 
in each formulation batch was known (2 mL solution with a doxycycline concentration of 
20 mg/mL), any doxycycline not found in the supernatant could be assigned to the 
particles. Doxycycline in the supernatant was quantified using a Nano-drop 
spectrophotometer (ND-1000), which has an absorbance precision of 0.003 at 1 mm 
(0.01 cm) path length. According to the Beer-Lambert Equation, the doxycycline 
concentration, c, is given by c=A/εL, where A is light absorbance at 220 nm wavelength, 
ε is the molar absorptivity coefficient (121.39 M-1 cm-1), and L is the path length (0.01 
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cm). All measurements were performed in triplicate (n=3). The encapsulation efficiency 
(EE, %) was calculated using equation 3:  
 
 
 
 
 
5.2.5. Assessment of Drug Release 
To determine the rate at which doxycycline was released by the nanoparticles, the 
particles were resuspended in a drug-free solution that was analyzed for doxycycline 
content at predetermined time interval. To begin, dried fresh nanoparticles of known 
antibiotic content were first resuspended in 2 mL of nanopure water. A small aliquot of 
this particle-laden solution was then added to PBS-ethanol solution to produce a final 
volume of 2 mL with an initial concentration of 100-µg doxycycline per mL. This solution 
was incubated at 37°C under gentle agitation. At each specified time point (0.5, 1, 2, 3, 
4, 5, 6, 7, 8, 16, and 24 hours) thereafter, the sample was centrifuged and the 
supernatant was isolated and analyzed by Nano-drop spectrophotometry to determine 
the amount of doxycycline in solution. All measurements were performed in triplicate 
(n=3) for each formulation. The percentage of drug released at each time point was 
calculated according to equation 4:  
 
 
 
5.2.6. Antimicrobial Activity Assessment 
To determine the antibacterial activity of the doxycycline-loaded chitosan 
nanoparticles, minimum inhibitory concentrations (MICs) and minimum bactericidal 
concentrations (MBCs) were evaluated. The procedures for both assays were adopted 
from Lee et al.106 MIC is the lowest concentration of DCNPs that inhibits bacterial 
(3) EE (%) =  Drug Used @Synthesis (mg/mL) 
Drug Used @ Synthesis (mg/mL) – Free Drug in Supernatant (mg/mL) ________________________________________________________ × 100 
(4) Drug Release (%) =  Initial Drug in Particles (µg/mL) 
____________________ × 100 Drug in Solution (µg/mL) 
 55 
growth. For our analyses, a visual turbidimetric method was used. Freshly prepared 
nanoparticles, blank and drug-loaded, were UV-sterilized for ten minutes. The particles 
were then resuspended in a volume of sterile water sufficient to achieve a final 
doxycycline concentration of 100 µg/mL. A 500 µL aliquot of this solution with sterilized 
particles was added to a tube containing Luria-Bertani (LB) broth for a total volume of 2 
mL. A serial dilution, with a dilution factor of 0.3, was performed for the remaining six 
tubes. A parallel series of experiments was also run using unencapsulated doxycycline.  
Under sterile conditions, the tubes containing particles were inoculated with 1.0×105 
colony-forming units (CFUs)/mL of Escherichia coli cells in LB broth, then incubated at 
37°C under agitation for four hours. Following the incubation, the tubes were assessed 
visually for the appearance of turbidity (i.e., bacterial growth). Among the tubes that 
showed no visual turbidity—that is, complete inhibition of visible E. coli growth—the one 
with the lowest doxycycline concentration was identified as the MIC tube for that series. 
All MIC tubes were analyzed to assess the amount of bacteria present by measuring 
optical density of the suspension at 600 nm (OD600) and then calculating the number of 
bacterial cells present. 
The MBC is the minimum concentration of DCNPs that will kill 99% of the bacterial 
cells initially present. To determine this value, 100 µL aliquots of liquid culture (broth + 
nanoparticles + bacteria) from each series’ MIC tube and the two tubes prior (i.e., 
containing slightly more doxycycline) were plated and incubated at 37°C overnight. As a 
positive control, an additional plate was plated with broth plus E. coli (no particles or 
drug); as a negative control, another plate was plated with broth plus blank particles plus 
E. coli (no drug). All samples were plated in triplicate. Plates were observed for colony 
growth, and the plate with the fewest colony colonies was identified as the MBC plate. 
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5.2.7. Cytotoxicity Assessment 
Cytotoxicity of the DCNPs was determined by treating normal human ovarian surface 
epithelial (OSE) cells with different concentrations of doxycycline-loaded nanoparticles, 
then monitoring cell viability over the next five days. The OSE cells were cultured for 4 to 
7 days in flasks containing medium199/MCDB105 media supplemented with 10% fetal 
bovine serum. The cells were removed from the flasks and counted, and then 100 µL of 
medium containing cells was added to the wells of a 96-well plate to give final cell 
concentrations of 5×102, 1.0×103, or 2.0×103cells/mL. After 24 hours incubation at 37°C, 
the cells were treated with blank nanoparticles, DCNP4 (1 and 2 µg/mL), DCNP6 (1 and 
2 µg/mL), or unencapsulated doxycycline (1 and 2 µg/mL). The plate was then incubated 
at 37°C. Bright microscopy was used to examine the cell morphology after treatment just 
before the assessing for cytotoxicity. Cytotoxicity was assessed on days 1, 3, and 5 by 
WST-1 assay. WST-1 assay reagent (10 µL) was added to each well, followed by 
incubation for another 4 hours at 37°C and then spectrophotometric assessment of cell 
viability.Mitochondrial dehydrogenases produced by viable cells reduce the WST-1 
reagent to form formazan dye in an amount directly proportional to the number of 
metabolically active cells in the well. This dye was quantified using a Biotex Synergy 
multiplate reader to measure absorbance at 450 nm (reference wavelength was 630 
nm). All treatments were assayed in triplicate (n=3) and calculated according to equation 
5:  
 
 
  
(5) Cell Viability (%) =  OD450 of Treated Cells 
__________________ × 100 
OD450 of Treated Cells  
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5.2.8. Statistical Analysis 
A two-way analysis of variance (ANOVA) was employed to identify statistical 
differences among the various experimental groups and their corresponding control 
groups. Experimental groups with p-values of p<0.05 were considered to be statistically 
significant. 
 
5.3. Results and Discussion 
5.3.1. Characterization of Doxycycline Loaded Nanoparticles 
Blank and doxycycline-loaded chitosan nanoparticles were successfully prepared 
using an ionic gelation method. The blank particles, BKCNP4 and BKCNP6, were 
relatively large, with an average diameter of 4,900 nm and 4,450 nm, respectively (data 
not shown). Both groups of particles were spherical in shape with a narrow particle size 
distribution. The drug-loaded particles were smaller than their blank counterparts. The 
DCNP4 particles (Figure 5-1(a)), with an average particle diameter of 44.50 nm, were 
two orders of magnitude smaller than their corresponding blanks and had a wider 
particle size distribution profile. DCNP4s were spherical in shape with smooth edges 
(Figure 5-1(b)). Similarly, the DCNP6 particles (Figure 5-1(c)), with an average diameter 
of 280 nm, were small compared to their blank counterparts—about 1/15 the size--but 
were significantly larger than the DCNP4s. In contrast to the DCNP4s, the DCNP6 
particles exhibited a very narrow particle size distribution profile. The DCNP6 particles 
were spherical like the DCNP4s but had edges that were not as smooth (Figure 5-1(d)). 
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Figure 5-1: Particle size distribution and TEM images for DCNP4 (top) and DCNP6 
(bottom). 
 
Since the conditions that varied between the two formulations for preparing these 
particles was the concentration of the TPP crosslinker and the resulting ratio of chitosan 
to TPP, based on the data from the previous chapter, we now know that the 
concentration of the crosslinker plays a role in determining particle size. Also, inclusion 
of the doxycycline in the formulations produced particles significantly smaller than the 
blanks, which is an interesting finding that our group is currently investigating. Having a 
narrower particle size distribution profile—i.e., particles of more uniform size--is also 
important. The more similar the particles are in size, the more equally the drug will be 
distributed among the particles, which will normalize the rate of drug release.  
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5.3.2. Encapsulation Efficiency 
Across all batches of DCNP4, the lowest encapsulation efficiency was 22%, the 
highest was 69%, and the average was 53%±19. For DCNP6, the lowest encapsulation 
efficiency was 41%, the highest was 68%, and the average was 56%±10. Even though 
DCNP6 was substantially larger in diameter, there was no significant difference in the 
amount of drug encapsulated for each type of DCNP. 
 
5.3.3. Drug Release 
Doxycycline was released from the DCNPs in a burst-effect manner followed by a 
slow sustained release (Figure 5-2). For DCNP4, the burst effect occurred within the first 
five hours; for DCNP6, within the first four hours. Within the first couple of hours after 
this initial burst, the amount of drug released decreased, then, it was followed by a 
sustained release for the remaining time.  By the end of the 24-hour monitoring period, 
DCNP6 had released more total drug than the DCNP4. The difference between the 
amounts of drug released by the two different particle formulations can be attributed to 
the differences in particle size, with the larger particles (DCNP6) releasing more 
antibiotic than the smaller ones (DCNP4). A burst effect followed by slow sustained 
release, as demonstrated by both nanoparticle formulations, is ideal for treating 
microbial infections such as PID. For PID, delivering the particles in a local (i.e., 
transcervical) manner to the reproductive lumen would provide an increasing amount of 
doxycycline in the beginning, followed by a reduced amount afterwards. This would 
increase the likelihood of total pathogen elimination.  
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Figure 5-2: The amount of doxycycline release over a 24-hour period for DCNP4 and 
DCNP6. Both had an initial burst effect within the first four to five hours. Then, there was 
a decrease in the amount of drug being released followed by a slow sustained amount 
for the remaining hours. Data shown are the mean ± standard deviation (n=3). 
 
5.3.4. Antimicrobial Activity Assessment 
After four hours incubation at 37°C, the drug-loaded nanoparticles' minimum 
inhibitory doxycycline concentration, MIC, was 16 µg/mL for DCNP4 and 13 µg/mL for 
DCNP6. Figure 5-3 shows the MIC cases for DCNP4 (16 µg/mL) and DCNP6 (13 
µg/mL) with unencapsulated doxycycline (Doxy-13µg/mL) and blank particles serving as 
controls. For both types of DCNPs, more than 92% E. coli growth inhibition was 
observed. The minimum bactericidal concentration, MBC, was 48 µg/mL and 40 µg/mL 
for DCNP4 and DCNP6, respectively. Unencapsulated doxycycline treatments (Doxy), 
conducted at the same concentrations as the DCNP drug concentrations, resulted in the 
near-elimination of E. coli. These data suggest that the unencapsulated doxycycline had 
a higher antibacterial activity than the DCNPs within the four-hour period. However, 
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because the DCNPs release the doxycycline in a slow and sustained manner, we 
speculate that the nanoparticles' antibacterial activity would have been higher if the 
incubation period had been extended beyond four hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3: Inhibitory effects of drug-loaded chitosan nanoparticles on bacterial growth, 
expressed in terms of percentage of remaining bacteria after four hours of treatment. 
MIC values are as follow: DCNP4 = 16 µg/mL, DCNP6 = 13 µg/mL, and Doxy = 13 
µg/mL. The untreated tube was used to define the "100% remaining" (no inhibition) case. 
Data shown are the mean ± standard deviation (n=3). 
 
5.3.5. Cytotoxicity Assessment 
For the case of initial human ovarian surface epithelial (OSE) cell densities of 5×102, 
no cytotoxicity (relative to the cells-only case) was induced by the 1 µg/mL or 2 µg/mL 
dosages of either DCNP formulation. In other words, cells treated with the DCNPs for 
five days showed high cell viability (Figure 5-4). In fact, a significant increase in cell 
proliferation relative to the cells-only case was often observed when the OSE cells were 
treated with blank or doxycycline-loaded nanoparticles. In contrast, unencapsulated 
doxycycline at the same dosages induced severe cell toxicity: only 39% of the original 
!
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population remained viable after the five-day treatment. Cells treated with both dosages 
of DCNP4 or with BKCNP4 had a higher viability than the untreated cells. For DCNP6, 
the viability of cells treated with 1 µg/mL was higher than for untreated cells, but cells 
treated with 2 µg/mL showed lower viability. Nevertheless, the DCNP6 case still showed 
greater cell viability than the unencapsulated drug treatments. Data from the wells with 
1.0×103 and 2.0×103 initial cell densities are not presented because of cell overcrowding 
over the five-day period.  
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Figure 5-4: Five-day cell viability for human ovarian surface epithelial cells exposed to 
blank nanoparticles, drug-loaded nanoparticles, and unencapsulated doxycycline. A 
higher formazan absorbance indicates greater cell viability. Data shown are the mean ± 
standard deviation (n=3).  
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These cytotoxicity results show that encapsulation of doxycycline into the chitosan 
polymer reduces the toxicity that is normally induced by the unencapsulated drug. The 
differences between the DCNP4 and DCNP6 cytotoxicity results are possibly due to the 
differences in their size and the amount of drug released. The DCNP6s were observed 
to release more doxycycline than the DCNP4s. Further exploration and evaluation of the 
effects of chitosan particles on cell growth is necessary to explain the observed increase 
in proliferation. 
Doxycycline-induced cytotoxicity was confirmed visually through observations of cell 
morphology following exposure to doxycycline.  Cells treated with 1 µg/mL and 2 µg/mL 
dosages of doxycycline show the morphology of dead cells. The morphological effects of 
treating with DCNP4 (at 2 µg/mL) and unencapsulated doxycycline (also at 2 µg/mL) are 
illustrated in Figure 5-5. Note that the cells treated with the DCNPs were of the same 
morphology as the untreated cells. This further demonstrates that encapsulation of 
doxycycline into chitosan nanoparticles minimizes the adverse effects of the drug.  
 65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5: Bright-field images of human ovarian surface epithelial cells after being 
exposed to the different treatments. (a) No treatment (control), (b) doxycycline at 2 
µg/mL, and (c) DCNP4 at 2 µg/mL. Magnification 10X.  
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5.4. Summary 
Doxycycline-loaded chitosan nanoparticles were synthesized and characterized to 
analyze their properties for targeted drug delivery. Two types of nanoparticles were 
formulated with differing concentrations of crosslinker: DCNP4 and DCNP6. The DCNP6 
formulation contained approximately 1.5 times more TPP crosslinker than DCNP4. 
Results showed that both types of drug-loaded chitosan nanoparticles were spherical, 
with encapsulation efficiencies of approximately 50%, and with a similar drug release 
profile. Both formulations also inhibited the growth of Escherichia coli after four hours of 
incubation. MBC (minimum bactericidal concentration) values were less than 50 µg/mL. 
The DCNPs induced significantly less apparent cytotoxicity than the unencapsulated 
doxycycline. These results demonstrate that the encapsulation of doxycycline into 
chitosan nanoparticles has the potential to minimize adverse drug side effects.  
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Chapter 6 - Summary, Conclusions, and Future Work 
 
This chapter provides a summary of the research work and findings of the 
dissertation. The conclusions are discussed here followed by a description of future 
research work. 
 
6.1. Summary 
This dissertation focused on the design and validation of a new device and approach 
to collect sterile specimen samples from the endometrium for more accurate PID 
diagnosis, and to locally treat PID using doxycycline-loaded chitosan nanoparticles. In 
the first part of this dissertation, we designed and developed a sterile uterine sampler 
device for uncontaminated endometrium sampling. Then, we analyzed the ionic gelation 
method for preparing the doxycycline-loaded chitosan nanoparticles and identified 
relationships between the variables and particle size. Finally, we studied the in vitro 
antibacterial and cytotoxicity effects of the doxycycline-loaded chitosan nanoparticles. 
A novel single use sterile uterine sampler cover (SUSC) device was designed and 
developed that has two main functions: to safely and effectively collect uncontaminated 
specimen samples from the uterus, and to deliver nano-encapsulated drugs directly to 
the site of infection. The developed device was designed to accommodate any size of 
cervices and collect up adequate specimen sample. The device was validated using an 
agar sampling test that demonstrated the capability of the presented SUSC device to 
significantly reduce contamination of the collected sample.  
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In the second part of the dissertation, we analyzed twelve preparatory variables 
relevant in determining chitosan particle sizes by the ionic gelation method. Statistical 
analysis was performed to select significant variables that were used to build an optimal 
model for determining the particle size. The statistical study showed that the mean 
particle diameter of chitosan particles (drug-free or drug-loaded) prepared by the ionic 
gelation method can be manipulated by varying four key formulation parameters. Based 
on two independent statistical methods, these parameters are: the chitosan-to-TPP ratio, 
wash/resuspension solution, synthesis time, and TPP concentration. These four 
variables contributed to 58% of the total variation in observed particle size. Mean particle 
diameter was found to be directly proportional to synthesis time and inversely 
proportional to the chitosan-to-TPP ratio and TPP concentration. In other words, 
increasing the chitosan-to-TPP ratio, and TPP concentration while lowering the 
synthesis time can lead to the formation of smaller particles. Using PBS as the 
wash/resuspension solution instead of water also decreases the particle size. In 
addition, it was observed that dissolving or protonating chitosan in acetic acid of 
concentration higher than 0.25M resulted in chitosan degradation. From the TEM 
studies, it was observed that centrifugation (rather than passive settling) of the particles 
followed by resuspension in nanopure water (rather than PBS) result in severe particle 
clumping (aggregate) and larger particle diameters. 
In the third part of the dissertation, two particle formulations were examined in more 
detail: formulation DCNP6 containing approximately 1.5 times the crosslinker 
concentration of the other formulation named DCNP4. Both formulations produced 
spherically shaped drug-loaded nanoparticles. The spheres ranged in size from 30 to 
220 nm diameter for DCNP4 and 200 to 320 nm diameter for DCNP6. Average 
encapsulation yield was 53% for DCNP4 and 56% for DCNP6. In terms of drug release, 
both formulations showed a burst effect within the first four to five hours, followed by a 
 69 
slow sustained release for the remainder of the 24-hour monitoring period. The in vitro 
antibacterial activity against Escherichia coli was high, with both formulations achieving 
more than 90% inhibition of four-hour bacterial growth. Cytotoxic effects of the DCNPs 
on normal human ovarian surface epithelial cells were significantly lower than those of 
unencapsulated doxycycline. After five days, cultures exposed to the unencapsulated 
antibiotic showed a 61% decrease in cell viability, while cultures exposed to the DCNPs 
exhibited less than a 10% decrease. 
 
6.2. Conclusions 
This dissertation presented a new device and nanoparticle-based approach to 
improve the accuracy of diagnosis and treatment of pelvic inflammatory disease (PID). A 
new device was developed to procure sterile specimen samples from the endometrium 
by passing through highly contaminated vaginal and distal cervical areas. It is expected 
that the analysis of uncontaminated endometrium tissue samples will provide accurate 
diagnosis of PID, the specific organism causing it, and the particular drug to be 
administered. The presented device can also be used for directly delivering 
nanoencapsulated drugs at the site of infection. We analyzed the encapsulation of 
doxycycline into chitosan nanoparticles using the ionic gelation method to better 
understand the size variation of the particles produced through this method. Four 
preparatory variables were selected as being significantly influential in determining 
particle size. Eventually, this work can lead to higher control of particle size and 
morphology (shape), which may in turn facilitate the use of the ionic gelation method for 
mass production of chitosan particles for drug delivery systems. Finally, we 
demonstrated that doxycycline-loaded chitosan nanoparticles have the potential for 
treating E. coli, a common co-pathogen in pelvic inflammatory disease, in a slow 
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sustained manner without inducing any apparent cellular toxicity to the non-bacterial 
cells. These laboratory results suggest that doxycycline-loaded chitosan nanoparticles 
show promise for use in transcervical drug delivery and improved efficacy in the 
treatment of bacterial uterine infections. These results also demonstrate that the 
encapsulation of doxycycline into chitosan nanoparticles can minimize the adverse side 
effects of the drug while also beneficially releasing the drug in a slow and sustained 
manner. 
The findings of this dissertation research are not only beneficial for the diagnostic of 
PID but also for localized delivery of nanoencapsulated drugs to the uterus. 
Uncontaminated samples will allow a better understanding of the natural microbial 
ecology of the uterus under a variety of spontaneous and manipulated hormonal 
conditions. It is highly likely that microfilms of dormant pathogens exist in the 
endometrial cavity as they do in the inner ear, bladder and prostate, and this has 
enormous implications for fertility and complications of pregnancy. The SUSC device 
can also be used for addressing other gynecological disorders/problems such as 
removal of obstructions in the fallopian tubes, and targeted sperm delivery. 
 
6.3. Future Work 
Based on the findings of this dissertation, the following future studies are 
recommended. 
 
6.3.1. SUSC Device Clinical Testing 
Once the patent process of the device is completed, the SUSC device will be 
manufactured so that it can be eventually approved for clinical testing. First, the proper 
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IRA will be filed and upon approval from the IRA office, patients undergoing 
hysterectomy will be asked to consider being a volunteer in our clinical testing. 
 
6.3.2. Cellular Growth Induced by Chitosan Particles 
From the cytotoxicity work, we found that the blank nanoparticles induce cellular 
growth. Future work will consist of studying whether the blank and drug-loaded particles 
used in this study induce cell proliferation in other cell types. Contingent upon the result 
of those preliminary studies, chitosan could be studied for its potential role in wound 
healing. 
 
6.3.3. The Effect of DCNPs on Intracellular Organisms 
Based on the results from this dissertation, we demonstrated that the chitosan 
nanoparticles are entering the cells. We also know that the DCNPs are inhibiting the 
growth of E. coli. The next step is to evaluate the effects of the DCNPs on intracellular 
infectious organisms such as Neisseria gonorrhoeae and Chlamydia trachomatis, which 
contribute to two of the most common sexual transfected diseases. In order to treat 
infections that are caused by intracellular organisms, the drug needs to be delivered into 
the cells/tissues. The nanoparticle delivery system presented in this dissertation would 
be ideal for treating these types of infections. 
 
6.3.4. Biofilm Studies 
In this dissertation, we analyzed the effect of the doxycycline-loaded chitosan 
nanoparticles against E.coli in planktonic conditions. Based on the results from chapter 
5, the next step would be to analyze the effect of the doxycycline-loaded chitosan 
nanoparticles in a biofilm system, preferably a biofilm model that is similar to that of the 
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uterus biofilm. Results from inhibitory tests done in a biofilm system will improve the 
clinical value for future application of these doxycycline-loaded chitosan nanoparticles in 
drug delivery. 
 
6.3.5. Animal Studies 
After studying the doxycycline-loaded chitosan in a biofilm model, these particles can 
then be evaluated in vivo. We know from the in vitro studies that the chitosan 
nanoparticles do not induce any form of cytotoxicity. However, it is important to know 
how these nanoparticles will function in an animal model. At this phase of the study, the 
particles should be delivered in a transcervical manner with a miniature version of the 
SUSC device. An ideal animal model would be one that has an infection in the uterus 
similar to PID on humans.  
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Appendix A: A Copy of the Pre-Development Survey 
I. Purpose of survey: A Research group from the University of South Florida is 
conducting a prescreening survey about the development of a new medical 
device. The research group will use the data from this survey as the criteria for 
device development. 
 
II. Targeted end-users: Obstetricians and Gynecologists 
 
III. Proposed device function: To collect uncontaminated endometrium samples 
 
IV. Your participation is important: Participation in this survey is voluntary. 
However, your cooperation is essential to the accuracy in prioritizing the criteria 
used for device development. The data reported on the questionnaire will be 
used for statistical purposes in ranking criteria. 
 
Questions: 
1. Are there presently any devices used to collect uncontaminated specimen 
from the uterus? 
a. Yes 
b. No 
2. Rate the following criteria in order of importance on a scale of 1-5, with 1, 
being the most important to 5, the least: 
a. Comfort to patient 
b. Prevent contamination 
c. Ease of handling 
d. Device Durability 
e. Dimension of device 
3. What is the major problem/difficulty in collecting uncontaminated 
specimen from the uterus?  
a. No proven device is available 
b. Avoiding contamination by vaginal flora 
c. Painful procedure for the patient  
d. Laboratory wont identified organisms beyond the “normal genital 
flora” 
e. Other 
4. What type of sampler, do you currently use for endometrium biopsy? 
a. SelectCell 
b. SelectCell Mini 
c. Pipelle 
d. Tao Brush  
e. Milex Pipet Curet 
f. Uterine Explora Model 1 
g. Other 
5. Do you think there is need for a device that will collect uncontaminated 
uterine samples to diagnose possible uterine diseases? 
a. Yes 
b. No 
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Appendix B: List of the 64 Formulations of Chitosan Nanoparticles 
Each formulation was done in triple and then all three trials were averaged. The 
average particle size is represented in the last column. 
 
 
  
F CS_TYPE CS_CONC CS_SOLV PRO_TIME TPP_CONC TPP_SOLV DRUG ORDER RATIO SYN_TIME CENTRI REC_SOLV AVERAGE PAR_SIZE
1 0 0.2 0 60 0.84 0 1 0 4 60 1 1 90
2 0 0.2 0 60 0.84 0 1 0 4 60 1 1 155
3 0 0.1 0 60 0.21 0 0 1 4 60 1 1 33
4 0 0.1 0 60 0.42 0 0 1 4 60 1 1 114
5 0 0.1 0 30 0.42 0 0 1 4 120 0 1 99.5
6 0 0.1 0 30 0.42 0 0 1 4 1440 0 1 415
7 0 0.1 0 30 0.42 0 0 1 4 60 0 1 142
8 0 0.2 0 60 0.84 0 1 1 4 1440 1 1 3486
9 0 0.1 0 60 0.42 0 1 1 4 1440 1 1 4905
10 1 0.2 1 1440 0.84 1 1 0 2 60 1 0 102
11 1 0.2 1 1440 0.84 1 1 0 2 60 1 0 143
12 1 0.2 1 1440 0.84 1 1 0 2 60 0 0 169.5
13 0 0.2 1 1440 0.84 1 1 0 2 60 1 0 427
14 0 0.2 1 1440 0.84 1 1 0 1 60 1 0 320
15 0 0.2 1 1440 0.84 1 1 1 2 60 1 0 620
16 1 0.2 1 1440 0.84 1 1 0 1 60 1 0 600
17 0 0.2 1 1440 0.84 1 1 0 1 60 1 1 4000
18 1 0.2 1 1440 0.84 1 1 0 1 60 0 1 4000
19 0 0.2 1 1440 0.84 1 1 0 1 120 0 1 6000
20 1 0.2 1 1440 0.84 1 1 0 1 120 0 1 3550
21 0 0.2 1 1440 0.84 1 1 0 1 120 1 1 4450
22 1 0.2 1 1440 0.84 1 1 0 1 120 1 1 5700
23 0 0.2 1 1440 0.84 1 1 1 2 120 0 1 575
24 1 0.2 1 1440 0.84 1 1 1 2 120 0 1 2000
25 0 0.2 1 1440 0.84 1 1 1 2 60 0 0 595
26 0 0.2 1 1440 0.42 1 1 1 2 60 0 0 265
27 0 0.2 1 1440 0.84 1 1 0 2 60 0 0 3250
28 0 0.2 1 1440 0.42 1 1 0 2 60 0 0 4000
29 1 0.2 1 1440 0.84 1 1 1 2 60 0 0 3500
30 1 0.2 1 1440 0.84 1 1 0 2 60 0 0 3175
31 1 0.2 1 1440 0.42 1 1 1 2 60 1 0 70
32 1 0.2 1 1440 0.42 1 1 0 2 60 0 0 3750
33 0 0.2 1 1440 0.75 1 1 1 2 60 0 0 685
34 0 0.2 1 1440 0.6 1 1 1 2 60 0 0 255
35 1 0.2 1 1440 0.75 1 1 1 2 60 0 0 1500
36 1 0.2 1 1440 0.6 1 1 1 2 60 0 0 675
37 1 0.1 1 60 0.42 0 0 1 1 60 1 0 5450
38 1 0.1 1 60 0.42 0 0 1 1 60 0 0 3500
39 1 0.1 1 60 0.42 0 1 1 1 60 1 0 4000
40 1 0.1 1 60 0.42 0 1 1 1 60 0 0 4250
41 1 0.2 1 60 0.42 0 0 1 1 60 1 0 5000
42 1 0.2 1 60 0.42 0 0 1 1 60 0 0 4000
43 1 0.2 1 60 0.42 0 1 1 1 60 1 0 3500
44 1 0.2 1 60 0.42 0 1 1 1 60 0 0 2500
45 1 0.1 0 60 0.42 0 0 1 1 60 1 0 4050
46 1 0.1 0 60 0.42 0 0 1 1 60 0 0 4050
47 1 0.1 0 60 0.42 0 1 1 1 60 1 0 3750
48 1 0.1 0 60 0.42 0 1 1 1 60 0 0 2600
49 1 0.2 0 60 0.42 0 0 1 1 60 1 0 2545
50 1 0.2 0 60 0.42 0 0 1 1 60 0 0 2550
51 1 0.2 0 60 0.42 0 1 1 1 60 1 0 3550
52 1 0.2 0 60 0.42 0 1 1 1 60 0 0 1600
53 1 0.1 1 1440 0.42 0 0 1 1 60 1 1 3000
54 1 0.1 1 1440 0.42 0 0 1 1 60 0 1 3950
55 1 0.1 1 1440 0.42 0 1 1 1 60 1 1 5000
56 1 0.1 1 1440 0.42 0 1 1 1 60 0 1 6000
57 1 0.2 1 1440 0.42 0 0 1 1 60 1 1 950
58 1 0.2 1 1440 0.42 0 0 1 1 60 0 1 5500
59 1 0.2 1 1440 0.42 0 1 1 1 60 1 1 5550
60 1 0.2 1 1440 0.42 0 1 1 1 60 0 1 5050
61 1 0.1 1 1440 0.42 1 0 1 1 60 1 1 5000
62 1 0.1 1 1440 0.42 1 0 1 1 60 0 1 4100
63 1 0.1 1 1440 0.42 1 1 1 1 60 1 1 5900
64 1 0.1 1 1440 0.42 1 1 1 1 60 0 1 5300
 84 
Appendix C: AIC-Based Stepwise Selection Conditional Tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
AIC-based stepwise forward selection (RDA) 
Conditional Tests: (each variable separately) 
RSS  R2 R2adj AIC Wts Delta Ratio Variables 
1.7401e+08  0.3105 0.2994 952.4053 0 0.9958 1  Chitosan:TPP Ratio 
2.0692e+08  0.1802 0.1669 963.4904 11.0851 0.0039 255.3269 Chitosan Type 
2.3345e+08  0.0750 0.0601 971.2121 18.8068 8.2099e-05 1.2129e+04 TPP Concentration 
2.3659e+08  0.0626 0.0475 972.0659 19.6606 5.3571e-05 1.8589e+04 Chitosan Concentration 
2.3771e+08  0.0582 0.0430 972.3683 19.9630 4.6054e-05 2.1623e+04 Wash/Reconstitution Solution 
2.3964e+08  0.0505 0.0352 972.8854 20.4801 3.5562e-05 2.8002e+04 Chitosan Dissolving Solution 
2.5239e+08 NaN NaN 974.0718 21.6665 1.9650e-05 5.0678e+04 None 
2.4539e+08  0.0277 0.0121 974.4036 21.9983 1.6646e-05 5.9823e+04 TPP Dissolving solution 
2.4995e+08  0.0097 -0.0063 975.5816 23.1763 9.2365e-06 1.0781e+05 Order 
2.5196e+08  0.0017 -0.0144 976.0933 23.6880 7.1515e-06 1.3925e+05  Protonation Time 
2.5203e+08  0.0014 -0.0147 976.1125 23.7072 7.0832e-06 1.4059e+05 Drug 
2.5222e+08  6.6606e-04 -0.0155 976.1614 23.7561 6.9121e-06 1.4407e+05 Synthesis Time 
2.5239e+08  5.0692e-07 -0.0161 976.2040 23.7987 6.7664e-06 1.4717e+05 Centrifugation 
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Appendix D: AIC-Based Stepwise Selection Marginal Tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
AIC-based stepwise forward selection (RDA) 
Marginal Tests: (sequential variable addition) 
RSS R2 R2adj AIC Wts DeltaN Variables 
1.7401e+08 0.3105 0.2994 952.4053 0.9958 21.6665 Ratio 
1.3499e+08 0.4652 0.4476 938.3569 0.8535 14.0484 Wash/Reconstitution 
Solution 
1.1456e+08 0.5461 0.5234 930.1306 0.7613 8.2263 Synthesis Time 
1.0698e+08 0.5761 0.5474 928.1074 0.2282 2.0232 TPP Concentration 
1.0698e+08 NaN NaN 928.1074 0.2034 0 None 
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Appendix E: Stepwise Redundancy Analysis Global Test 
 
 
Stepwise REDUNDANCY ANALYSIS 
Global Test: (all variables included) 
F p R2 R2adj 
7.7013 1.0000e-03 0.6444 0.5607 
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Appendix F: Stepwise Redundancy Analysis Conditional Tests 
 
 
Stepwise REDUNDANCY ANALYSIS 
Conditional Tests: (each variable separately) 
F p R2 R2adj Variables 
13.6248 1.0000e-03 0.1802 0.1669  Chitosan Type 
4.1412 0.0540 0.0626 0.0475 Chitosan Concentration 
3.2997 0.0790 0.0505 0.0352 Chitosan Dissolving Solution 
0.1074 0.7450 0.0017 -0.0144 Protonation Time 
5.0296 0.0330 0.0750 0.0601 TPP Concentration 
1.7689 0.1870 0.0277 0.0121 TPP Dissolving solution 
0.0887 0.7730 0.0014 -0.0147 Drug 
0.6059 0.4250 0.0097 -0.0063 Order 
27.9262 1.0000e-03 0.3105 0.2994 Ratio 
0.0413 0.8440 6.6606e-04 -0.0155 Synthesis Time 
3.1429e-05 0.9950 5.0692e-07 -0.0161 Centrifugation 
3.8295 0.0520 0.0582 0.0430 Wash/Reconstitution 
Solution 
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Appendix G: Stepwise Redundancy Analysis Marginal Tests 
 
 
Stepwise REDUNDANCY ANALYSIS 
Marginal Tests: (sequential variable addition) 
Partial F P Partial R2 Partial R2adj Cum R2adj Variables 
27.9262 1.0000e-03  0.3105 0.2994 0.2994 Ratio 
17.6342 1.0000e-03 0.1546 0.1410 0.4476 Wash/Reconstitution 
Solution 
10.7019 0.0030 0.0810 0.0661 0.5234 Synthesis Time 
4.1789 0.0500 0.0300 0.0144 0.5474 TPP Concentration 
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Appendix H: Multiple Linear Regression via QR Factorization 
 
 
Multiple Linear Regression via QR Factorization 
R2 R2adj F-stat Para-p Perm-p 
0.57614 0.54740 20.04913 0.00000 0.00100  
 
 
Multiple Linear Regression via QR Factorization 
Variables b t-stat Parametric-p Permutation-p 
Intercept 6820.73439 11.24915 0.00000 0.00200 
1 -1520.19243 -7.86486 0.00000 0.00200 
2 -1383.24087 -3.89756 0.00024 0.00200 
3 2.19529 3.23940 0.00191 0.00200 
4 -1714.64471 -2.04425 0.04511 0.02400 
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Appendix I: Doxycycline Standard Curve 
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Appendix J: Hek 293 Transfected Cells with pGFP 
Shows the expression of pGFP in Hek 293 cells after transfected with pGFP-loaded 
chitosan nanoparticles prepared using the ionic gelation method day 3. 
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Appendix K: Day 1 WST-1 Raw Data for Formulation 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.278 0.287 0.261 0.58 0.626 0.621 0.976 1.009 0.914 1.703 1.766 1.814 450 
B 0.275 0.3 0.299 0.297 0.294 0.303 0.282 0.288 0.29 0.291 0.287 0.227 450 
C 0.379 0.378 0.427 0.55 0.628 0.567 0.871 0.915 0.953 0.282 0.285 0.28 450 
D 0.405 0.384 0.384 0.485 0.524 0.65 0.719 0.792 0.158 0.799 0.654 0.64 450 
E 0.512 0.537 0.653 1.035 0.953 1.02 1.47 1.546 1.451 0.809 0.9 0.86 450 
F 0.597 0.532 0.525 0.884 0.892 0.946 1.557 1.519 1.488 1.377 1.651 1.47 450 
G 0.048 0.05 0.047 0.047 0.047 0.05 0.047 0.048 0.047 0.047 0.047 0.046 450 
H 0.048 0.048 0.048 0.047 0.047 0.046 0.046 0.046 0.047 0.047 0.047 0.046 450 
                1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.184 0.19 0.173 0.293 0.312 0.309 0.442 0.462 0.448 0.763 0.752 0.785 490 
B 0.179 0.196 0.196 0.194 0.193 0.198 0.187 0.19 0.191 0.191 0.189 0.152 490 
C 0.225 0.229 0.235 0.271 0.277 0.283 0.369 0.38 0.386 0.186 0.188 0.185 490 
D 0.237 0.232 0.226 0.266 0.271 0.303 0.333 0.346 0.106 0.411 0.328 0.339 490 
E 0.274 0.283 0.333 0.462 0.433 0.45 0.626 0.689 0.669 0.402 0.426 0.434 490 
F 0.313 0.287 0.283 0.415 0.434 0.452 0.669 0.673 0.669 0.556 0.701 0.678 490 
G 0.046 0.047 0.044 0.044 0.044 0.048 0.044 0.045 0.044 0.044 0.045 0.045 490 
H 0.045 0.045 0.046 0.045 0.045 0.044 0.044 0.044 0.044 0.044 0.044 0.044 490 
                1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.051 0.051 0.047 0.049 0.05 0.05 0.051 0.053 0.052 0.054 0.055 0.053 630 
B 0.051 0.053 0.052 0.05 0.053 0.053 0.053 0.052 0.05 0.05 0.05 0.046 630 
C 0.053 0.054 0.053 0.054 0.054 0.053 0.056 0.058 0.056 0.05 0.05 0.05 630 
D 0.055 0.054 0.053 0.055 0.055 0.056 0.056 0.057 0.042 0.068 0.052 0.053 630 
E 0.05 0.051 0.053 0.054 0.052 0.053 0.056 0.057 0.057 0.054 0.055 0.053 630 
F 0.054 0.059 0.052 0.052 0.055 0.054 0.054 0.055 0.056 0.052 0.056 0.055 630 
G 0.043 0.045 0.041 0.041 0.043 0.045 0.042 0.042 0.041 0.042 0.043 0.043 630 
H 0.043 0.042 0.042 0.042 0.044 0.043 0.042 0.041 0.043 0.041 0.043 0.041 630 
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Appendix L: Day 3 WST-1 Raw Data for Formulation 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.292 0.304 0.313 1.078 1.02 0.956 1.473 1.398 1.22 0.522 0.535 0.53 450 
B 0.312 0.319 0.331 0.328 0.326 0.297 0.297 0.31 0.297 0.323 0.309 0.33 450 
C 0.399 0.41 0.389 0.421 0.454 0.613 0.607 0.59 0.67 0.31 0.326 0.334 450 
D 0.372 0.393 0.37 0.399 0.371 0.373 0.447 0.463 0.47 1.062 0.938 1.057 450 
E 0.99 1.193 1.094 1.543 1.532 1.549 1.494 1.594 1.891 1.468 1.3 1.341 450 
F 1.143 1.163 1.183 1.584 1.805 1.555 1.26 1.155 1.097 1.424 0.813 1.042 450 
G 0.056 0.049 0.047 0.047 0.047 0.059 0.047 0.047 0.051 0.047 0.047 0.047 450 
H 0.047 0.049 0.047 0.047 0.046 0.046 0.047 0.047 0.047 0.056 0.047 0.046 450 
                1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.183 0.19 0.192 0.497 0.494 0.481 0.675 0.658 0.591 0.271 0.275 0.275 490 
B 0.193 0.196 0.201 0.198 0.197 0.19 0.19 0.195 0.192 0.202 0.188 0.2 490 
C 0.248 0.233 0.223 0.23 0.241 0.311 0.279 0.287 0.309 0.195 0.204 0.204 490 
D 0.222 0.225 0.219 0.226 0.217 0.221 0.238 0.252 0.251 0.444 0.419 0.511 490 
E 0.455 0.484 0.468 0.663 0.648 0.642 0.657 0.702 0.754 0.641 0.587 0.634 490 
F 0.517 0.502 0.522 0.683 0.726 0.649 0.535 0.513 0.493 0.612 0.383 0.495 490 
G 0.054 0.047 0.044 0.044 0.044 0.057 0.045 0.045 0.048 0.045 0.045 0.045 490 
H 0.044 0.046 0.045 0.045 0.044 0.045 0.045 0.045 0.045 0.053 0.044 0.044 490 
                1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.048 0.05 0.046 0.051 0.051 0.05 0.056 0.057 0.055 0.055 0.053 0.054 630 
B 0.049 0.051 0.05 0.048 0.048 0.049 0.049 0.049 0.047 0.049 0.048 0.05 630 
C 0.077 0.053 0.052 0.051 0.05 0.061 0.052 0.053 0.051 0.049 0.052 0.05 630 
D 0.054 0.052 0.052 0.052 0.053 0.052 0.049 0.053 0.053 0.051 0.051 0.054 630 
E 0.053 0.052 0.051 0.054 0.055 0.054 0.057 0.062 0.063 0.057 0.057 0.056 630 
F 0.055 0.052 0.051 0.057 0.056 0.054 0.058 0.069 0.062 0.057 0.058 0.06 630 
G 0.049 0.044 0.041 0.041 0.043 0.054 0.043 0.042 0.044 0.043 0.043 0.043 630 
H 0.041 0.042 0.041 0.042 0.043 0.043 0.042 0.042 0.042 0.05 0.042 0.042 630 
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Appendix M: Day 5 WST-1 Raw Data for Formulation 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.458 0.464 0.438 1.268 1.065 1.044 0.631 0.564 0.609 0.869 0.935 0.842 450 
B 0.474 0.462 0.38 0.4 0.423 0.382 0.429 0.409 0.423 0.424 0.445 0.436 450 
C 0.52 0.489 0.428 0.422 0.455 0.432 0.503 0.495 0.491 0.44 0.451 0.384 450 
D 0.527 0.46 0.441 0.442 0.433 0.445 0.429 0.484 0.461 1.649 1.311 1.446 450 
E 1.697 1.997 1.652 1.475 1.384 1.441 1.366 1.292 1.166 1.393 0.864 1.402 450 
F 1.872 1.871 1.696 0.925 1.624 2.019 1.05 1.057 0.937 0.868 0.864 0.904 450 
G 0.047 0.047 0.049 0.048 0.047 0.047 0.047 0.047 0.047 0.049 0.048 0.046 450 
H 0.049 0.047 0.049 0.046 0.048 0.046 0.046 0.046 0.046 0.048 0.048 0.049 450 
                1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.281 0.279 0.263 0.64 0.536 0.565 0.356 0.307 0.338 0.492 0.538 0.422 490 
B 0.287 0.281 0.257 0.25 0.255 0.247 0.262 0.254 0.262 0.267 0.262 0.265 490 
C 0.31 0.289 0.281 0.251 0.281 0.281 0.295 0.291 0.287 0.27 0.274 0.229 490 
D 0.319 0.299 0.271 0.289 0.27 0.278 0.255 0.293 0.286 0.664 0.587 0.672 490 
E 0.768 0.865 0.722 0.656 0.672 0.624 0.611 0.571 0.53 0.614 0.43 0.656 490 
F 0.841 0.815 0.757 0.459 0.712 0.862 0.481 0.505 0.467 0.441 0.441 0.445 490 
G 0.045 0.045 0.046 0.045 0.045 0.045 0.045 0.045 0.045 0.046 0.046 0.044 490 
H 0.046 0.044 0.046 0.044 0.046 0.044 0.044 0.044 0.044 0.045 0.045 0.047 490 
                1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.059 0.056 0.053 0.065 0.068 0.068 0.068 0.063 0.059 0.119 0.144 0.061 630 
B 0.059 0.059 0.055 0.053 0.055 0.054 0.056 0.057 0.055 0.055 0.056 0.055 630 
C 0.062 0.059 0.058 0.052 0.057 0.058 0.06 0.06 0.058 0.056 0.058 0.051 630 
D 0.064 0.063 0.06 0.061 0.059 0.056 0.057 0.06 0.062 0.061 0.065 0.06 630 
E 0.065 0.067 0.066 0.072 0.07 0.071 0.083 0.059 0.082 0.072 0.07 0.068 630 
F 0.065 0.066 0.064 0.069 0.064 0.061 0.054 0.057 0.059 0.061 0.068 0.071 630 
G 0.041 0.043 0.042 0.043 0.043 0.042 0.043 0.042 0.041 0.044 0.043 0.043 630 
H 0.044 0.04 0.043 0.041 0.044 0.043 0.042 0.041 0.041 0.041 0.043 0.043 630 
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Appendix N: Day 1 WST-1 Raw Data for Formulation 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1 2 3 4 5 6 7 8 9 10 11 12 
 0.148 0.179 0.191 0.835 0.851 0.83 0.838 1.006 0.796 1.613 1.668 1.58 450 
0.195 0.181 0.192 0.207 0.202 0.207 0.206 0.197 0.196 0.202 0.197 0.195 450 
0.557 0.632 0.627 0.636 0.642 0.595 0.951 0.994 0.957 0.196 0.189 0.198 450 
0.497 0.473 0.491 0.492 0.524 0.5 0.828 0.739 0.648 0.83 0.72 0.663 450 
0.676 0.805 0.749 0.723 0.766 0.72 1.408 1.142 1.28 0.916 0.734 0.711 450 
0.612 0.529 0.66 0.666 0.758 0.694 1.111 1.136 1.05 1.241 1.538 1.109 450 
0.047 0.047 0.047 0.047 0.047 0.047 0.047 0.047 0.053 0.047 0.047 0.047 450 
0.047 0.047 0.047 0.046 0.047 0.046 0.047 0.047 0.046 0.047 0.047 0.047 450 
             1 2 3 4 5 6 7 8 9 10 11 12 
 0.106 0.126 0.134 0.392 0.393 0.385 0.409 0.457 0.375 0.666 0.712 0.668 490 
0.134 0.127 0.136 0.143 0.14 0.142 0.149 0.141 0.14 0.142 0.14 0.143 490 
0.263 0.288 0.301 0.312 0.304 0.292 0.412 0.416 0.442 0.14 0.136 0.142 490 
0.258 0.248 0.252 0.264 0.265 0.253 0.373 0.347 0.312 0.388 0.337 0.326 490 
0.311 0.354 0.341 0.326 0.35 0.327 0.589 0.517 0.557 0.426 0.345 0.351 490 
0.296 0.249 0.325 0.325 0.358 0.336 0.47 0.525 0.465 0.538 0.649 0.478 490 
0.045 0.045 0.044 0.044 0.044 0.045 0.044 0.044 0.051 0.045 0.045 0.044 490 
0.044 0.045 0.044 0.044 0.044 0.044 0.045 0.044 0.044 0.044 0.044 0.044 490 
             1 2 3 4 5 6 7 8 9 10 11 12 
 0.039 0.039 0.038 0.042 0.041 0.041 0.045 0.046 0.041 0.043 0.045 0.045 630 
0.04 0.04 0.04 0.039 0.04 0.041 0.048 0.04 0.04 0.039 0.039 0.041 630 
0.042 0.042 0.042 0.042 0.042 0.041 0.044 0.043 0.044 0.04 0.039 0.041 630 
0.043 0.042 0.042 0.044 0.044 0.042 0.043 0.043 0.045 0.044 0.042 0.041 630 
0.041 0.042 0.042 0.043 0.041 0.041 0.043 0.044 0.045 0.043 0.042 0.042 630 
0.041 0.043 0.044 0.042 0.046 0.043 0.043 0.054 0.044 0.044 0.044 0.045 630 
0.043 0.042 0.041 0.042 0.043 0.042 0.042 0.041 0.048 0.043 0.042 0.043 630 
0.042 0.04 0.041 0.041 0.042 0.042 0.042 0.041 0.041 0.042 0.042 0.042 630 
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Appendix O: Day 3 WST-1 Raw Data for Formulation 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.186 0.189 0.191 1.621 1.837 2.17 1.789 2.469 2.908 2.321 2.086 2.275 450 
B 0.259 0.278 0.274 0.292 0.28 0.286 0.275 0.272 0.265 0.273 0.281 0.265 450 
C 1.161 0.965 0.962 0.944 1.28 1.154 1.708 1.616 1.348 0.277 0.271 0.28 450 
D 0.404 0.461 0.495 0.471 0.578 0.57 0.747 0.833 0.886 1.488 1.93 1.425 450 
E 1.941 1.812 2.135 1.526 1.658 1.68 2.705 2.63 2.918 1.626 1.878 1.437 450 
F 0.907 1.081 1.025 0.69 0.965 0.922 1.735 1.408 1.537 2.07 1.815 2.013 450 
G 0.048 0.047 0.061 0.048 0.047 0.047 0.047 0.05 0.049 0.052 0.047 0.048 450 
H 0.047 0.046 0.047 0.049 0.047 0.05 0.046 0.047 0.047 0.048 0.047 0.047 450 
                1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.132 0.134 0.135 0.765 0.775 0.847 0.831 0.938 0.939 0.902 0.854 0.955 490 
B 0.171 0.187 0.183 0.194 0.184 0.19 0.19 0.186 0.182 0.187 0.192 0.181 490 
C 0.515 0.425 0.472 0.381 0.5 0.436 0.607 0.555 0.562 0.189 0.183 0.194 490 
D 0.227 0.245 0.24 0.244 0.262 0.284 0.339 0.329 0.359 0.591 0.796 0.628 490 
E 0.764 0.742 0.808 0.597 0.656 0.755 1.041 1.079 1.192 0.714 0.788 0.641 490 
F 0.399 0.444 0.419 0.331 0.42 0.393 0.759 0.601 0.647 0.88 0.792 0.874 490 
G 0.045 0.045 0.057 0.045 0.045 0.045 0.045 0.047 0.046 0.05 0.046 0.046 490 
H 0.044 0.044 0.044 0.046 0.044 0.047 0.044 0.044 0.046 0.045 0.045 0.045 490 
                1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.04 0.04 0.039 0.045 0.044 0.048 0.049 0.047 0.047 0.051 0.054 0.053 630 
B 0.042 0.043 0.042 0.041 0.042 0.042 0.044 0.043 0.042 0.042 0.042 0.042 630 
C 0.046 0.045 0.047 0.046 0.045 0.044 0.05 0.05 0.048 0.042 0.043 0.043 630 
D 0.043 0.045 0.044 0.044 0.047 0.042 0.045 0.044 0.055 0.058 0.048 0.046 630 
E 0.047 0.046 0.047 0.045 0.044 0.047 0.052 0.057 0.052 0.056 0.047 0.046 630 
F 0.046 0.048 0.05 0.046 0.045 0.045 0.05 0.051 0.053 0.055 0.054 0.048 630 
G 0.043 0.042 0.051 0.043 0.043 0.042 0.043 0.044 0.043 0.046 0.043 0.044 630 
H 0.043 0.04 0.04 0.044 0.043 0.045 0.041 0.041 0.041 0.043 0.042 0.043 630 
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Appendix P: Day 5 WST-1 Raw Data for Formulation 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.401 0.395 0.389 1.246 0.87 1.186 0.921 0.85 0.812 1.202 1.04 0.927 450 
B 0.389 0.393 0.376 0.38 0.382 0.38 0.362 0.372 0.361 0.363 0.373 0.353 450 
C 0.825 0.834 0.82 0.785 0.815 0.962 1.085 0.989 0.842 0.375 0.379 0.381 450 
D 0.423 0.435 0.431 0.44 0.43 0.448 0.587 0.461 0.467 1.271 3.073 2.811 450 
E 2.572 2.343 2.432 2.172 2.324 2.223 2.326 0.815 0.965 1.169 1.25 1.088 450 
F 1.358 1.442 1.141 1.474 1.525 1.29 1.262 0.874 1.198 1.173 0.868 1.012 450 
G 0.047 0.048 0.048 0.047 0.05 0.048 0.057 0.049 0.062 0.048 0.048 0.048 450 
H 0.047 0.048 0.047 0.048 0.047 0.047 0.051 0.047 0.047 0.047 0.047 0.048 450 
                1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.273 0.269 0.267 0.54 0.402 0.482 0.456 0.449 0.43 0.598 0.551 0.477 490 
B 0.274 0.274 0.259 0.26 0.263 0.261 0.255 0.262 0.254 0.256 0.262 0.242 490 
C 0.401 0.419 0.409 0.441 0.405 0.438 0.503 0.618 0.464 0.266 0.268 0.27 490 
D 0.288 0.284 0.304 0.299 0.299 0.294 0.33 0.304 0.305 0.609 1.401 1.23 490 
E 0.989 1.913 1.953 1.904 2.059 2.047 1.114 0.515 0.53 0.518 0.663 0.541 490 
F 0.652 0.696 0.571 0.571 0.684 0.503 0.757 0.503 0.644 0.603 0.498 0.522 490 
G 0.044 0.045 0.045 0.045 0.044 0.045 0.053 0.046 0.058 0.045 0.046 0.045 490 
H 0.044 0.045 0.045 0.045 0.044 0.045 0.048 0.045 0.045 0.044 0.044 0.045 490 
                1 2 3 4 5 6 7 8 9 10 11 12 
 A 0.044 0.045 0.044 0.05 0.049 0.051 0.054 0.055 0.05 0.059 0.061 0.059 630 
B 0.046 0.047 0.045 0.044 0.045 0.047 0.047 0.047 0.045 0.045 0.044 0.044 630 
C 0.049 0.049 0.049 0.048 0.049 0.049 0.052 0.051 0.052 0.047 0.046 0.046 630 
D 0.048 0.049 0.049 0.05 0.05 0.047 0.048 0.051 0.052 0.052 0.05 0.052 630 
E 0.053 0.076 0.057 0.058 0.084 0.086 0.066 0.061 0.061 0.056 0.056 0.055 630 
F 0.049 0.048 0.049 0.055 0.052 0.05 0.058 0.064 0.059 0.059 0.059 0.053 630 
G 0.042 0.042 0.041 0.042 0.042 0.042 0.049 0.044 0.053 0.043 0.043 0.044 630 
H 0.043 0.041 0.041 0.043 0.042 0.043 0.044 0.042 0.04 0.043 0.042 0.043 630 
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